{"id": "moa.assertion:66", "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:43", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Gorre, Mercedes E., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293.5531 (2001): 876-880.", "url": "https://doi.org/10.1126/science.1062538", "doi": "10.1126/science.1062538", "pmid": 11423618}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:66", "label": "ABL1 p.T315I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748283", "end_position": "133748283", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "66"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913459"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "type": "Allele", "digest": "D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:68", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:68", "label": "ABL1 p.T315A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747582", "end_position": "133747582", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.943A>G", "protein_change": "p.T315A", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "68"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519772"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.37YVc2HpRgXOq3HtsjcL1eiyLhDXLmYy", "type": "Allele", "digest": "37YVc2HpRgXOq3HtsjcL1eiyLhDXLmYy", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:69", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:66", "label": "ABL1 p.T315I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748283", "end_position": "133748283", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "66"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913459"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "type": "Allele", "digest": "D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:70", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:70", "label": "ABL1 p.F317L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748290", "end_position": "133748290", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.951C>G", "protein_change": "p.F317L", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "70"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.ZJZc_8PkTSu-twmaJvj6yQXvPJHElPZc", "type": "Allele", "digest": "ZJZc_8PkTSu-twmaJvj6yQXvPJHElPZc", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:71", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:71", "label": "ABL1 p.F317V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.949T>G", "protein_change": "p.F317V", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "71"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519773"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.SnGz3wUT2JaIid12PoI6OHc4t7LgHVj1", "type": "Allele", "digest": "SnGz3wUT2JaIid12PoI6OHc4t7LgHVj1", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:72", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:72", "label": "ABL1 p.F317I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.949T>A", "protein_change": "p.F317I", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "72"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519773"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.wDDVWfpuxnuYkLj5_0OrnaBvrJAXYcJA", "type": "Allele", "digest": "wDDVWfpuxnuYkLj5_0OrnaBvrJAXYcJA", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:73", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:73", "label": "ABL1 p.F317C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747586", "end_position": "133747586", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.950T>G", "protein_change": "p.F317C", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "73"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.qm_zti_uhENk10RV6-usf5CEKRGSHbm8", "type": "Allele", "digest": "qm_zti_uhENk10RV6-usf5CEKRGSHbm8", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:75", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:75", "label": "ABL1 p.E255K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738306", "end_position": "133738306", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.763G>A", "protein_change": "p.E255K", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "75"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs387906517"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.y7kX_U01bDeLnxvbo1BcNTnELH7f_x7V", "type": "Allele", "digest": "y7kX_U01bDeLnxvbo1BcNTnELH7f_x7V", "location": {"id": "ga4gh:SL.aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "type": "SequenceLocation", "digest": "aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 254, "end": 255}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:76", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:76", "label": "ABL1 p.E255V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738307", "end_position": "133738307", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.764A>T", "protein_change": "p.E255V", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "76"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs387906516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.v-kV7I4CYEDwUUB60OXG1kJDs5jXzAzj", "type": "Allele", "digest": "v-kV7I4CYEDwUUB60OXG1kJDs5jXzAzj", "location": {"id": "ga4gh:SL.aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "type": "SequenceLocation", "digest": "aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 254, "end": 255}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:77", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:77", "label": "ABL1 p.Y253H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738357", "end_position": "133738357", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.757T>C", "protein_change": "p.Y253H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "77"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913461"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.74tNeU5kbvRxbJbZ4y4HkTh0zV8u18IW", "type": "Allele", "digest": "74tNeU5kbvRxbJbZ4y4HkTh0zV8u18IW", "location": {"id": "ga4gh:SL.qgRBISQgsJA7fp25Ffb7YD7rdLjyqSO5", "type": "SequenceLocation", "digest": "qgRBISQgsJA7fp25Ffb7YD7rdLjyqSO5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 252, "end": 253}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:78", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:78", "label": "ABL1 p.F359V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1075T>G", "protein_change": "p.F359V", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913452"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.whkYT34c9xLuVqgpE0_pETIIQGkrgb8c", "type": "Allele", "digest": "whkYT34c9xLuVqgpE0_pETIIQGkrgb8c", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:79", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:79", "label": "ABL1 p.F359C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748358", "end_position": "133748358", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1076T>G", "protein_change": "p.F359C", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "79"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.m9irj_tUdc3UiH7iFOINzZzHZTCEAyCi", "type": "Allele", "digest": "m9irj_tUdc3UiH7iFOINzZzHZTCEAyCi", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:80", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:44", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": 27760149}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:80", "label": "ABL1 p.F359I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1075T>A", "protein_change": "p.F359I", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "80"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913452"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.B6uOm51_KWfoJlGO61ui7ltRfb4sG092", "type": "Allele", "digest": "B6uOm51_KWfoJlGO61ui7ltRfb4sG092", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:81", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:77", "label": "ABL1 p.Y253H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738357", "end_position": "133738357", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.757T>C", "protein_change": "p.Y253H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "77"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913461"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.74tNeU5kbvRxbJbZ4y4HkTh0zV8u18IW", "type": "Allele", "digest": "74tNeU5kbvRxbJbZ4y4HkTh0zV8u18IW", "location": {"id": "ga4gh:SL.qgRBISQgsJA7fp25Ffb7YD7rdLjyqSO5", "type": "SequenceLocation", "digest": "qgRBISQgsJA7fp25Ffb7YD7rdLjyqSO5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 252, "end": 253}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:82", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:75", "label": "ABL1 p.E255K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738306", "end_position": "133738306", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.763G>A", "protein_change": "p.E255K", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "75"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs387906517"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.y7kX_U01bDeLnxvbo1BcNTnELH7f_x7V", "type": "Allele", "digest": "y7kX_U01bDeLnxvbo1BcNTnELH7f_x7V", "location": {"id": "ga4gh:SL.aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "type": "SequenceLocation", "digest": "aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 254, "end": 255}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:83", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:76", "label": "ABL1 p.E255V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738307", "end_position": "133738307", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.764A>T", "protein_change": "p.E255V", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "76"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs387906516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.v-kV7I4CYEDwUUB60OXG1kJDs5jXzAzj", "type": "Allele", "digest": "v-kV7I4CYEDwUUB60OXG1kJDs5jXzAzj", "location": {"id": "ga4gh:SL.aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "type": "SequenceLocation", "digest": "aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 254, "end": 255}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:84", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:78", "label": "ABL1 p.F359V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1075T>G", "protein_change": "p.F359V", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913452"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.whkYT34c9xLuVqgpE0_pETIIQGkrgb8c", "type": "Allele", "digest": "whkYT34c9xLuVqgpE0_pETIIQGkrgb8c", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:85", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:79", "label": "ABL1 p.F359C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748358", "end_position": "133748358", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1076T>G", "protein_change": "p.F359C", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "79"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.m9irj_tUdc3UiH7iFOINzZzHZTCEAyCi", "type": "Allele", "digest": "m9irj_tUdc3UiH7iFOINzZzHZTCEAyCi", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:86", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:80", "label": "ABL1 p.F359I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1075T>A", "protein_change": "p.F359I", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "80"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913452"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.B6uOm51_KWfoJlGO61ui7ltRfb4sG092", "type": "Allele", "digest": "B6uOm51_KWfoJlGO61ui7ltRfb4sG092", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:87", "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:70", "label": "ABL1 p.F317L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748290", "end_position": "133748290", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.951C>G", "protein_change": "p.F317L", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "70"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.ZJZc_8PkTSu-twmaJvj6yQXvPJHElPZc", "type": "Allele", "digest": "ZJZc_8PkTSu-twmaJvj6yQXvPJHElPZc", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:88", "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:71", "label": "ABL1 p.F317V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.949T>G", "protein_change": "p.F317V", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "71"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519773"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.SnGz3wUT2JaIid12PoI6OHc4t7LgHVj1", "type": "Allele", "digest": "SnGz3wUT2JaIid12PoI6OHc4t7LgHVj1", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:89", "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:72", "label": "ABL1 p.F317I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.949T>A", "protein_change": "p.F317I", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "72"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519773"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.wDDVWfpuxnuYkLj5_0OrnaBvrJAXYcJA", "type": "Allele", "digest": "wDDVWfpuxnuYkLj5_0OrnaBvrJAXYcJA", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:90", "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:73", "label": "ABL1 p.F317C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747586", "end_position": "133747586", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.950T>G", "protein_change": "p.F317C", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "73"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.qm_zti_uhENk10RV6-usf5CEKRGSHbm8", "type": "Allele", "digest": "qm_zti_uhENk10RV6-usf5CEKRGSHbm8", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:91", "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:68", "label": "ABL1 p.T315A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747582", "end_position": "133747582", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.943A>G", "protein_change": "p.T315A", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "68"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519772"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.37YVc2HpRgXOq3HtsjcL1eiyLhDXLmYy", "type": "Allele", "digest": "37YVc2HpRgXOq3HtsjcL1eiyLhDXLmYy", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:92", "description": "Nilotinib (Tasigna) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:92", "label": "ABL1 p.V299L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747531", "end_position": "133747531", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.895G>T", "protein_change": "p.V299L", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "92"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.EhSHoRNbPVLi2cIM8uy9iiZQFnVc2QPp", "type": "Allele", "digest": "EhSHoRNbPVLi2cIM8uy9iiZQFnVc2QPp", "location": {"id": "ga4gh:SL.8Q5r34MRwwe75j2Yqz3UdE4YYoomdr84", "type": "SequenceLocation", "digest": "8Q5r34MRwwe75j2Yqz3UdE4YYoomdr84", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 298, "end": 299}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:662281", "label": "Nilotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:662281", "label": "nilotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:93", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:75", "label": "ABL1 p.E255K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738306", "end_position": "133738306", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.763G>A", "protein_change": "p.E255K", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "75"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs387906517"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.y7kX_U01bDeLnxvbo1BcNTnELH7f_x7V", "type": "Allele", "digest": "y7kX_U01bDeLnxvbo1BcNTnELH7f_x7V", "location": {"id": "ga4gh:SL.aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "type": "SequenceLocation", "digest": "aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 254, "end": 255}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:94", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:76", "label": "ABL1 p.E255V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738307", "end_position": "133738307", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.764A>T", "protein_change": "p.E255V", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "76"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs387906516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.v-kV7I4CYEDwUUB60OXG1kJDs5jXzAzj", "type": "Allele", "digest": "v-kV7I4CYEDwUUB60OXG1kJDs5jXzAzj", "location": {"id": "ga4gh:SL.aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "type": "SequenceLocation", "digest": "aVr5FRqrofr2Nu4YoLFf87JgSQIkssIm", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 254, "end": 255}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:95", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:70", "label": "ABL1 p.F317L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748290", "end_position": "133748290", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.951C>G", "protein_change": "p.F317L", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "70"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.ZJZc_8PkTSu-twmaJvj6yQXvPJHElPZc", "type": "Allele", "digest": "ZJZc_8PkTSu-twmaJvj6yQXvPJHElPZc", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:96", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:71", "label": "ABL1 p.F317V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.949T>G", "protein_change": "p.F317V", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "71"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519773"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.SnGz3wUT2JaIid12PoI6OHc4t7LgHVj1", "type": "Allele", "digest": "SnGz3wUT2JaIid12PoI6OHc4t7LgHVj1", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:97", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:72", "label": "ABL1 p.F317I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.949T>A", "protein_change": "p.F317I", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "72"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519773"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.wDDVWfpuxnuYkLj5_0OrnaBvrJAXYcJA", "type": "Allele", "digest": "wDDVWfpuxnuYkLj5_0OrnaBvrJAXYcJA", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:98", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:73", "label": "ABL1 p.F317C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747586", "end_position": "133747586", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.950T>G", "protein_change": "p.F317C", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "73"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.qm_zti_uhENk10RV6-usf5CEKRGSHbm8", "type": "Allele", "digest": "qm_zti_uhENk10RV6-usf5CEKRGSHbm8", "location": {"id": "ga4gh:SL.-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "type": "SequenceLocation", "digest": "-kNhxBY5Ce4osZrhr6PcndF9dVfZuhXl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 316, "end": 317}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:99", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:78", "label": "ABL1 p.F359V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1075T>G", "protein_change": "p.F359V", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "78"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913452"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.whkYT34c9xLuVqgpE0_pETIIQGkrgb8c", "type": "Allele", "digest": "whkYT34c9xLuVqgpE0_pETIIQGkrgb8c", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:100", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:79", "label": "ABL1 p.F359C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748358", "end_position": "133748358", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1076T>G", "protein_change": "p.F359C", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "79"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.m9irj_tUdc3UiH7iFOINzZzHZTCEAyCi", "type": "Allele", "digest": "m9irj_tUdc3UiH7iFOINzZzHZTCEAyCi", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:101", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:68", "label": "ABL1 p.T315A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133747582", "end_position": "133747582", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.943A>G", "protein_change": "p.T315A", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "68"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519772"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.37YVc2HpRgXOq3HtsjcL1eiyLhDXLmYy", "type": "Allele", "digest": "37YVc2HpRgXOq3HtsjcL1eiyLhDXLmYy", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:102", "description": "Bosutinib (Bosulif) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:77", "label": "ABL1 p.Y253H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133738357", "end_position": "133738357", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.757T>C", "protein_change": "p.Y253H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "77"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913461"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.74tNeU5kbvRxbJbZ4y4HkTh0zV8u18IW", "type": "Allele", "digest": "74tNeU5kbvRxbJbZ4y4HkTh0zV8u18IW", "location": {"id": "ga4gh:SL.qgRBISQgsJA7fp25Ffb7YD7rdLjyqSO5", "type": "SequenceLocation", "digest": "qgRBISQgsJA7fp25Ffb7YD7rdLjyqSO5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 252, "end": 253}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1307619", "label": "Bosutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1307619", "label": "bosutinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "EFO:0000339", "type": "Disease", "label": "chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:103", "description": "Ponatinib (Iclusig) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:66", "label": "ABL1 p.T315I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748283", "end_position": "133748283", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "66"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913459"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "type": "Allele", "digest": "D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1364347", "label": "Ponatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1364347", "label": "ponatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:104", "description": "Omacetaxine is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:66", "label": "ABL1 p.T315I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748283", "end_position": "133748283", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "exon": "5"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "66"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913459"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "type": "Allele", "digest": "D6NzpWXKqBnbcZZrXNSXj4tMUwROKbsQ", "location": {"id": "ga4gh:SL.jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "type": "SequenceLocation", "digest": "jGElwyBPYNWI-BkFFHKfgLJynt9zuNPs", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 314, "end": 315}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546446", "label": "Omacetaxine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546446", "label": "omacetaxine"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:105", "description": "Dasatinib (Sprycel) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with CML in the context of secondary resistance variants. Selection of an alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR::ABL1 mutant CML may be based on mutantion profile.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:45", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia V.2.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:80", "label": "ABL1 p.F359I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1075T>A", "protein_change": "p.F359I", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "80"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913452"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.B6uOm51_KWfoJlGO61ui7ltRfb4sG092", "type": "Allele", "digest": "B6uOm51_KWfoJlGO61ui7ltRfb4sG092", "location": {"id": "ga4gh:SL.eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "type": "SequenceLocation", "digest": "eHYdaAxNKYvTniglPlpffQGSwo5Z86Qe", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.dmFigTG-0fY6I54swb7PoDuxCeT6O3Wg"}, "start": 358, "end": 359}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1546019", "label": "Dasatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1546019", "label": "dasatinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3174", "label": "Chronic Myelogenous Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3174", "label": "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "mondo_id": "0011996"}}], "mappings": [{"coding": {"label": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org/", "code": "CML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ABL1", "label": "ABL1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:76"}], "type": "Gene"}}}
{"id": "moa.assertion:107", "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway. This study observed that AKT inhibitors MK-2206 and AZD5363 both caused significant growth inhibition of breast cancer explant models with AKT1 E17K mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:46", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1 E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.", "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230", "doi": "10.1158/1535-7163.MCT-15-0230", "pmid": 26351323}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:107", "label": "AKT1 p.E17K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "14", "start_position": "105246551", "end_position": "105246551", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.49G>A", "protein_change": "p.E17K", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "107"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs34409589"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.GfY89Zy-DJcnWtthBcoVV6PyuE4qkP8F", "type": "Allele", "digest": "GfY89Zy-DJcnWtthBcoVV6PyuE4qkP8F", "location": {"id": "ga4gh:SL.k8zRBGlFy4f7WSIlEKjXL6gH0LNrJpUr", "type": "SequenceLocation", "digest": "k8zRBGlFy4f7WSIlEKjXL6gH0LNrJpUr", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.GTSPIWYvuDZU59cW1RECFEU1FMiKdEyc"}, "start": 16, "end": 17}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.iuphar.ligand:7945", "label": "MK-2206", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "iuphar.ligand:7945", "label": "MK-2206"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:AKT1", "label": "AKT1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:391"}], "type": "Gene"}}}
{"id": "moa.assertion:110", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:48", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": 24675041}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:110", "label": "ALK p.G1202R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "29443613", "end_position": "29443613", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.3604G>A", "protein_change": "p.G1202R", "exon": "23"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "110"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519783"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.dW4kfzuGNeteFlDekXpEbr8I7sNkpdRn", "type": "Allele", "digest": "dW4kfzuGNeteFlDekXpEbr8I7sNkpdRn", "location": {"id": "ga4gh:SL.F3gyMEV6PxdjuC8YdS4xCe93ZgCfisMv", "type": "SequenceLocation", "digest": "F3gyMEV6PxdjuC8YdS4xCe93ZgCfisMv", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1201, "end": 1202}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1535457", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1535457", "label": "ceritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ALK", "label": "ALK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "type": "Gene"}}}
{"id": "moa.assertion:111", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:48", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": 24675041}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:111", "label": "ALK p.F1174C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "29443696", "end_position": "29443696", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.3521T>G", "protein_change": "p.F1174C", "exon": "23"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "111"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519697"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.qqPMMbmP3yREVCmNl-t9uErZKUttYH79", "type": "Allele", "digest": "qqPMMbmP3yREVCmNl-t9uErZKUttYH79", "location": {"id": "ga4gh:SL.XlFNNwHg2t7jH2X9fjfT1-6GCwTpCwj9", "type": "SequenceLocation", "digest": "XlFNNwHg2t7jH2X9fjfT1-6GCwTpCwj9", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1173, "end": 1174}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1535457", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1535457", "label": "ceritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ALK", "label": "ALK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "type": "Gene"}}}
{"id": "moa.assertion:112", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:48", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": 24675041}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:112", "label": "ALK p.L1196M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "29443631", "end_position": "29443631", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.3586C>A", "protein_change": "p.L1196M", "exon": "23"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "112"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519784"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.E8YabWqHYiNl5g4GUBxOIR3qT2Ni2hDX", "type": "Allele", "digest": "E8YabWqHYiNl5g4GUBxOIR3qT2Ni2hDX", "location": {"id": "ga4gh:SL.jNEhFKh0lI8CfRD8PWuWwNQuCQZ22ZS2", "type": "SequenceLocation", "digest": "jNEhFKh0lI8CfRD8PWuWwNQuCQZ22ZS2", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1195, "end": 1196}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1535457", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1535457", "label": "ceritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ALK", "label": "ALK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "type": "Gene"}}}
{"id": "moa.assertion:113", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:48", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": 24675041}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:113", "label": "ALK p.G1269A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "29432682", "end_position": "29432682", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.3806G>C", "protein_change": "p.G1269A", "exon": "25"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "113"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519781"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sfyM358Q8Jtl1wrMJOanYiOsDM3BVQPn", "type": "Allele", "digest": "sfyM358Q8Jtl1wrMJOanYiOsDM3BVQPn", "location": {"id": "ga4gh:SL.6XzUHqAGtgcgGHPemY47BEMozBrLNoKQ", "type": "SequenceLocation", "digest": "6XzUHqAGtgcgGHPemY47BEMozBrLNoKQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1268, "end": 1269}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1535457", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1535457", "label": "ceritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ALK", "label": "ALK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "type": "Gene"}}}
{"id": "moa.assertion:114", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:48", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": 24675041}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:114", "label": "ALK p.S1206Y (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "29443600", "end_position": "29443600", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.3617C>A", "protein_change": "p.S1206Y", "exon": "23"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "114"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519782"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.nq_fGAlsZnu7zjlISka1b1upudZGFuea", "type": "Allele", "digest": "nq_fGAlsZnu7zjlISka1b1upudZGFuea", "location": {"id": "ga4gh:SL.fee3DCrSu77T4amPR1lRjCQxU0hfh2bS", "type": "SequenceLocation", "digest": "fee3DCrSu77T4amPR1lRjCQxU0hfh2bS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs"}, "start": 1205, "end": 1206}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1535457", "label": "Ceritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1535457", "label": "ceritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ALK", "label": "ALK", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:427"}], "type": "Gene"}}}
{"id": "moa.assertion:115", "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:49", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.", "url": "https://doi.org/10.1158/1078-0432.CCR-14-1220", "doi": "10.1158/1078-0432.CCR-14-1220", "pmid": 25320358}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:115", "label": "AR p.T878A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "X", "start_position": "66943552", "end_position": "66943552", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.2632A>G", "protein_change": "p.T878A", "exon": "8"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "115"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs137852578"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.7f_c_kjvXs4sK9YEZXytxMRNhtOhfyrx", "type": "Allele", "digest": "7f_c_kjvXs4sK9YEZXytxMRNhtOhfyrx", "location": {"id": "ga4gh:SL.7C3gmOjCVP-VjOd0YFxg-1EktrlTEC3N", "type": "SequenceLocation", "digest": "7C3gmOjCVP-VjOd0YFxg-1EktrlTEC3N", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.3i2gUccySg7YHyjquhJ5ICgAPeHzvFFW"}, "start": 877, "end": 878}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1100071", "label": "Abiraterone", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1100071", "label": "abiraterone acetate"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2919", "label": "Prostate Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2919", "label": "Prostate Adenocarcinoma", "mondo_id": "0005082"}}], "mappings": [{"coding": {"label": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "PRAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:AR", "label": "AR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:644"}], "type": "Gene"}}}
{"id": "moa.assertion:116", "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:49", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.", "url": "https://doi.org/10.1158/1078-0432.CCR-14-1220", "doi": "10.1158/1078-0432.CCR-14-1220", "pmid": 25320358}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:116", "label": "AR p.L702H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "X", "start_position": "66931463", "end_position": "66931463", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.2105T>A", "protein_change": "p.L702H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "116"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.mXrc5IR5TO9WipB3sLeWDtzAYVHCFYki", "type": "Allele", "digest": "mXrc5IR5TO9WipB3sLeWDtzAYVHCFYki", "location": {"id": "ga4gh:SL.fJmEsPZu4CmU2rems1WTFE_ApDWY34Xx", "type": "SequenceLocation", "digest": "fJmEsPZu4CmU2rems1WTFE_ApDWY34Xx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.3i2gUccySg7YHyjquhJ5ICgAPeHzvFFW"}, "start": 701, "end": 702}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1100071", "label": "Abiraterone", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1100071", "label": "abiraterone acetate"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2919", "label": "Prostate Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2919", "label": "Prostate Adenocarcinoma", "mondo_id": "0005082"}}], "mappings": [{"coding": {"label": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "PRAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:AR", "label": "AR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:644"}], "type": "Gene"}}}
{"id": "moa.assertion:117", "description": "Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:50", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.", "url": "https://doi.org/10.1172/JCI72763", "doi": "10.1172/JCI72763", "pmid": 24569458}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:117", "label": "ARAF p.S214C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "X", "start_position": "47426121", "end_position": "47426121", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.641C>G", "protein_change": "p.S214C", "exon": "7"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "117"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.mipQFzApQNp2KyVXcZig8b4uu7kFofIZ", "type": "Allele", "digest": "mipQFzApQNp2KyVXcZig8b4uu7kFofIZ", "location": {"id": "ga4gh:SL.hH2CTbUukSXfWWuwbPAowFTYG3pxXWeL", "type": "SequenceLocation", "digest": "hH2CTbUukSXfWWuwbPAowFTYG3pxXWeL", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.zWUEijoFMvm7vDgj6af1ZwwBERSNnm4a"}, "start": 213, "end": 214}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:495881", "label": "Sorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:495881", "label": "sorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:65823", "type": "Disease", "label": "Thyroid cancer differentiated"}, {"id": "hemonc:612", "type": "Disease", "label": "Hepatocellular carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C3099"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ARAF", "label": "ARAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:646"}], "type": "Gene"}}}
{"id": "moa.assertion:129", "description": "HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:55", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.", "url": "https://doi.org/10.1016/j.tranon.2017.01.007", "doi": "10.1016/j.tranon.2017.01.007", "pmid": 28182994}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:129", "label": "ATM p.A1127D (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "11", "start_position": "108150313", "end_position": "108150313", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.3380C>A", "protein_change": "p.A1127D", "exon": "23"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "129"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1555090340"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.F81AHXva7dDDRrTA5kxObhJ4dQ8GQ6B8", "type": "Allele", "digest": "F81AHXva7dDDRrTA5kxObhJ4dQ8GQ6B8", "location": {"id": "ga4gh:SL.gc0pEFQHpDLuseicL8P7ODHGRGhSwvJO", "type": "SequenceLocation", "digest": "gc0pEFQHpDLuseicL8P7ODHGRGhSwvJO", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.6k1y4bTo7pEJ-a1GaniRBaCJXXGkBGFO"}, "start": 1126, "end": 1127}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1597582", "label": "Olaparib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1597582", "label": "olaparib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:645", "type": "Disease", "label": "Ovarian cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7431"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}, {"id": "hemonc:658", "type": "Disease", "label": "Prostate cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7378"}, "relation": "relatedMatch"}]}, {"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C5105", "label": "Colorectal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C5105", "label": "Colorectal Adenocarcinoma", "mondo_id": "0005008"}}], "mappings": [{"coding": {"label": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "COADREAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ATM", "label": "ATM", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:795"}], "type": "Gene"}}}
{"id": "moa.assertion:144", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:60", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:145", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:60", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:146", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:60", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:146", "label": "BRAF p.V600K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "146"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "type": "Allele", "digest": "pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:147", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:60", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:148", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:60", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:146", "label": "BRAF p.V600K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "146"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "type": "Allele", "digest": "pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:149", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:60", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:150", "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:61", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:151", "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:61", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:146", "label": "BRAF p.V600K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "146"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "type": "Allele", "digest": "pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:152", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:62", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:146", "label": "BRAF p.V600K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "146"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "type": "Allele", "digest": "pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049106", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049106", "label": "encorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:153", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:62", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049106", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049106", "label": "encorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:154", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:62", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:zBda4sO3iQLExj5SB8VTPzPLaPoWefiP", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:318341", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:318341", "label": "cetuximab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:2049106", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049106", "label": "encorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C5105", "label": "Colorectal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C5105", "label": "Colorectal Adenocarcinoma", "mondo_id": "0005008"}}], "mappings": [{"coding": {"label": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "COADREAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:155", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:63", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:156", "description": "Panitumumab (Vectibix) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic colorectal cancer, BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor. ", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:64", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.4.2018. \u00a9 National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed March 20 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:263034", "label": "Panitumumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:263034", "label": "panitumumab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C5105", "label": "Colorectal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C5105", "label": "Colorectal Adenocarcinoma", "mondo_id": "0005008"}}], "mappings": [{"coding": {"label": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "COADREAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:158", "description": "Vemurafenib (Zelboraf) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:66", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:159", "description": "Dabrafenib (Tafinlar) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:66", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:160", "description": "Vemurafenib (Zelboraf) in combination with Cobimetinib (Coltellic) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:66", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:dhs2LkZmpoTUpE6XlcACT7zTBbnvfnX9", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1722365", "label": "Cobimetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1722365", "label": "cobimetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:161", "description": "Dabrafenib (Tafinlar) in combination with Trametinib (Mekinist) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with BRAF p.V600E mutant melanoma. Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:66", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Melanoma V.3.2016. \u00a9 National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed November 5 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:162", "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:67", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01673854"}, "relation": "exactMatch"}], "type": "Document", "title": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", "url": "https://doi.org/10.1186/s40425-016-0148-7", "doi": "10.1186/s40425-016-0148-7", "pmid": 27532019}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:FKTdlTdqAvhIQciAr34sdnBlday3jJMR", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Combination therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1094833", "label": "Ipilimumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1094833", "label": "ipilimumab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:163", "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:67", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01673854"}, "relation": "exactMatch"}], "type": "Document", "title": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", "url": "https://doi.org/10.1186/s40425-016-0148-7", "doi": "10.1186/s40425-016-0148-7", "pmid": 27532019}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:FKTdlTdqAvhIQciAr34sdnBlday3jJMR", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Combination therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1094833", "label": "Ipilimumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1094833", "label": "ipilimumab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:164", "description": "Administration of bevacizumab in a dabrafenib-resistant melanoma cancer cell line (A375R) counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance. This study suggests that a regime which combines BRAFi with bevacizumab or inhibitors of PI3K/Akt/mTOR may be more effective than BRAFi monotherapy in the setting of resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:68", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", "url": "https://doi.org/10.3892/ijo.2016.3594", "doi": "10.3892/ijo.2016.3594", "pmid": 27572607}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:Q8MsBWnZEz9Ibgy9CFdvvd735aqANV8t", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:2046138", "label": "Bevacizumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2046138", "label": "bevacizumab-awwb"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002289", "type": "Disease", "label": "Carcinoma, Non-Small-Cell Lung", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "mesh:D003110", "type": "Disease", "label": "Colonic Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2953"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002583", "type": "Disease", "label": "Uterine Cervical Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C9311"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002292", "type": "Disease", "label": "Carcinoma, Renal Cell", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}, {"id": "mesh:D005909", "type": "Disease", "label": "Glioblastoma", "mappings": [{"coding": {"system": "ncit", "code": "C3058"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:165", "description": "Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance. This study suggests that a regime which combines BRAFi with bevacizumab or inhibitors of PI3K/Akt/mTOR may be more effective than BRAFi monotherapy in the setting of resistance.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:68", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", "url": "https://doi.org/10.3892/ijo.2016.3594", "doi": "10.3892/ijo.2016.3594", "pmid": 27572607}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:reZr1erbRlUj4i9sapm6pr2OzpdbGeWq", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.ncit:C88270", "label": "Omipalisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C88270", "label": "Omipalisib"}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:167", "description": "Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:70", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Fondello C, Agnetti L, Villaverde MS, Simian M, Glikin GC, Finocchiaro LM. The combination of bleomycin with suicide or interferon-beta gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomed Pharmacother. 2016;83:290-301.", "url": "https://doi.org/10.1016/j.biopha.2016.06.038", "doi": "10.1016/j.biopha.2016.06.038", "pmid": 27399807}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1622", "label": "Bleomycin", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1622", "label": "bleomycin"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:169", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:72", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01524978"}, "relation": "exactMatch"}], "type": "Document", "title": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": 26287849}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3107", "label": "Langerhans Cell Histiocytosis", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3107", "label": "Langerhans Cell Histiocytosis", "mondo_id": "0018310"}}], "mappings": [{"coding": {"label": "Langerhans Cell Histiocytosis", "system": "https://oncotree.mskcc.org/", "code": "LCH"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:170", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:72", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01524978"}, "relation": "exactMatch"}], "type": "Document", "title": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": 26287849}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C53972", "label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C53972", "label": "Erdheim-Chester Disease", "mondo_id": "0018153"}}], "mappings": [{"coding": {"label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "system": "https://oncotree.mskcc.org/", "code": "ECD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:171", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:72", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01524978"}, "relation": "exactMatch"}], "type": "Document", "title": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": 26287849}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:172", "description": "Study of a patient-derived orthotopic xenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:73", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Kawaguchi K, Murakami T, Chmielowski B, et al. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2016;", "url": "https://doi.org/10.18632/oncotarget.12328", "doi": "10.18632/oncotarget.12328", "pmid": 27690220}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:173", "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting over 7 months when treated with dabrafenib and trametinib in combination.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:74", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.", "url": "https://doi.org/10.1158/2159-8290.CD-15-1192", "doi": "10.1158/2159-8290.CD-15-1192", "pmid": 27048246}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.oncotree:HGNEC", "label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "oncotree:HGNEC", "label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "mondo_id": null}}], "mappings": [{"coding": {"label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "system": "https://oncotree.mskcc.org/", "code": "HGNEC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:174", "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting 9 months when treated with vemurafenib and trametinib in combination.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:74", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.", "url": "https://doi.org/10.1158/2159-8290.CD-15-1192", "doi": "10.1158/2159-8290.CD-15-1192", "pmid": 27048246}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:xQv-2m99rVOprssTMAjOqFqgoYXQuioO", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.oncotree:HGNEC", "label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "oncotree:HGNEC", "label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "mondo_id": null}}], "mappings": [{"coding": {"label": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "system": "https://oncotree.mskcc.org/", "code": "HGNEC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:175", "description": "Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:75", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Suarez-kelly LP, Kemper GM, Duggan MC, et al. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;", "url": "https://doi.org/10.18632/oncotarget.12791", "doi": "10.18632/oncotarget.12791", "pmid": 27783987}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:NmGaX2IchyPJJ5hrP9xxsLPbTPlUBTWc", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.ncit:C2220", "label": "Interferon-alpha", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C2220", "label": "Interferon Alfa-N1"}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1723735", "label": "Ixazomib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1723735", "label": "ixazomib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:180", "description": "BRAF V600E mutations were associated with sensitivity to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:52", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": 25855536}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C8294", "label": "Pancreatic Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C8294", "label": "Pancreatic Adenocarcinoma", "mondo_id": "0006047"}}], "mappings": [{"coding": {"label": "Pancreatic Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "PAAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:181", "description": "Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:77", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993-2005.", "url": "https://doi.org/10.18632/oncotarget.4014", "doi": "10.18632/oncotarget.4014", "pmid": 26023796}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:0trcUgfHzHFLIvacsRpjWHnI1eN8XvQc", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1940643", "label": "Neratinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1940643", "label": "neratinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.oncotree:GNOS", "label": "Glioma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "oncotree:GNOS", "label": "Glioma, NOS", "mondo_id": null}}], "mappings": [{"coding": {"label": "Glioma", "system": "https://oncotree.mskcc.org/", "code": "GNOS"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:182", "description": "Cetuximab (Erbitux) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with metastatic colorectal cancer, BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor. ", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:64", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer V.4.2018. \u00a9 National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed March 20 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:318341", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:318341", "label": "cetuximab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C5105", "label": "Colorectal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C5105", "label": "Colorectal Adenocarcinoma", "mondo_id": "0005008"}}], "mappings": [{"coding": {"label": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "COADREAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:184", "description": "Vemurafenib alone had insufficient activity in BRAF V600E mutant colorectal cancer patients. Of patients who received vemurafenib and cetuximab, one response was observed; however, approximately half of the patients had tumor regression that did not meet the standard criteria of partial response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:72", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01524978"}, "relation": "exactMatch"}], "type": "Document", "title": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": 26287849}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:Xu3LpnoQkk74JyWy2b90_Y6KSgb4Gdst", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:318341", "label": "Cetuximab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:318341", "label": "cetuximab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}, {"id": "mesh:D006258", "type": "Disease", "label": "Head and Neck Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C4013"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002294", "type": "Disease", "label": "Carcinoma, Squamous Cell", "mappings": [{"coding": {"system": "ncit", "code": "C2929"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C5105", "label": "Colorectal Adenocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C5105", "label": "Colorectal Adenocarcinoma", "mondo_id": "0005008"}}], "mappings": [{"coding": {"label": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "COADREAD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:242", "description": "Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDA approved test, whose disease has progressed on or after EGFR TKI therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:89", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1721560", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1721560", "label": "osimertinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:245", "description": "Gefitinib (Iressa) is not recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with second-site mutations within the EGFR kinase domain, such as p.T790M, as they are associated with acquired resistance to EGFR TKIs.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:20", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Lung Cancer V.1.2017. \u00a9 National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 5, 2016. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf"}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:328134", "label": "Gefitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:328134", "label": "gefitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:249", "description": "Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:90", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT02143466"}, "relation": "exactMatch"}], "type": "Document", "title": "Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4 Suppl):S115.", "url": "https://doi.org/10.1016/S1556-0864(16)30246-5", "doi": "10.1016/S1556-0864(16)30246-5", "pmid": 27599705}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.ctid:9vUH8jAN_UCLGblx4LtQdsL8c_EHtvE_", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Combination therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1919503", "label": "Durvalumab", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1919503", "label": "durvalumab"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D002289", "type": "Disease", "label": "Carcinoma, Non-Small-Cell Lung", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "mesh:D008175", "type": "Disease", "label": "Lung Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3200"}, "relation": "relatedMatch"}]}, {"id": "mesh:D055752", "type": "Disease", "label": "Small Cell Lung Carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4917"}, "relation": "relatedMatch"}]}, {"id": "mesh:D001749", "type": "Disease", "label": "Urinary Bladder Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1721560", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1721560", "label": "osimertinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:250", "description": "HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:91", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01588145"}, "relation": "exactMatch"}], "type": "Document", "title": "Park K, Lee J, Han J, et al. 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose Journal of Thoracic Oncology. 2016; 11(4):S113-.", "url": "https://doi.org/10.1016/S1556-0864(16)30243-X", "doi": "10.1016/S1556-0864(16)30243-X"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C101791", "label": "Olmutinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C101791", "label": "Olmutinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:254", "description": "Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:92", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01708954"}, "relation": "exactMatch"}], "type": "Document", "title": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/ 10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": 27717507}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:254", "label": "EGFR p.L858R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "254"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "location": {"id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2058848", "label": "Dacomitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2058848", "label": "dacomitinib anhydrous"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:256", "description": "Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:92", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01708954"}, "relation": "exactMatch"}], "type": "Document", "title": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/ 10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": 27717507}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1721560", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1721560", "label": "osimertinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:257", "description": "Rociletinib was found to be effective in some patients in a 130-patient trial.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:93", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01526928"}, "relation": "exactMatch"}], "type": "Document", "title": "Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-9.", "url": "https://doi.org/10.1056/NEJMoa1413654", "doi": "10.1056/NEJMoa1413654", "pmid": 25923550}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C99905", "label": "Rociletinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C99905", "label": "Rociletinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:259", "description": "Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:95", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": 27071706}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1721560", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1721560", "label": "osimertinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:260", "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:95", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": 27071706}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:254", "label": "EGFR p.L858R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "254"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "location": {"id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C115109", "label": "EGF816", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C115109", "label": "Nazartinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:261", "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:95", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": 27071706}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C115109", "label": "EGF816", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C115109", "label": "Nazartinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:262", "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:95", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": 27071706}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:254", "label": "EGFR p.L858R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "254"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "location": {"id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C120307", "label": "PF-06747775", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C120307", "label": "Mavelertinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:263", "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:95", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": 27071706}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C120307", "label": "PF-06747775", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C120307", "label": "Mavelertinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:264", "description": "TKI therapy for patients with T790M has limited benefit.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:96", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428.", "url": "https://doi.org/10.1093/annonc/mdt573", "doi": "10.1093/annonc/mdt573", "pmid": 24478319}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:337525", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:337525", "label": "erlotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:265", "description": "TKI therapy for patients with T790M has limited benefit.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:96", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428.", "url": "https://doi.org/10.1093/annonc/mdt573", "doi": "10.1093/annonc/mdt573", "pmid": 24478319}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:242", "label": "EGFR p.T790M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "exon": "20"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "242"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434569"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "type": "Allele", "digest": "sMA9h8fzDi0RvweMlxtD0_Oi8B-JZ1V-", "location": {"id": "ga4gh:SL.UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "type": "SequenceLocation", "digest": "UOSDv-_5QNbKqgbCf--isFjvNZ5ZST09", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 789, "end": 790}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1430438", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1430438", "label": "afatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:268", "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:97", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:254", "label": "EGFR p.L858R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "254"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "location": {"id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1430438", "label": "Afatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1430438", "label": "afatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:25316", "type": "Disease", "label": "Non-small cell lung cancer squamous"}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:271", "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:98", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated -Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med. 2018; 378(2):113-125.", "url": "https://doi.org/10.1056/NEJMoa1713137", "doi": "10.1056/NEJMoa1713137", "pmid": 29151359}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "interventional study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000006"}, "variant": {"id": "moa.variant:254", "label": "EGFR p.L858R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "254"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "location": {"id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1721560", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1721560", "label": "osimertinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:273", "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:99", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Revised December 2020. Accessed February 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:254", "label": "EGFR p.L858R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "254"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434568"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "location": {"id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE"}, "start": 857, "end": 858}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1721560", "label": "Osimertinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1721560", "label": "osimertinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EGFR", "label": "EGFR", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3236"}], "type": "Gene"}}}
{"id": "moa.assertion:281", "description": "Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:23", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.", "url": "https://doi.org/10.1371/journal.pgen.1004135", "doi": "10.1371/journal.pgen.1004135", "pmid": 24550739}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:281", "label": "ERRFI1 p.E384* (Nonsense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "8073509", "end_position": "8073509", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.1150G>T", "protein_change": "p.E384*", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "281"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.v5Jc64GQjTPVlsjiINmmlWmNRFfDDnoO", "type": "Allele", "digest": "v5Jc64GQjTPVlsjiINmmlWmNRFfDDnoO", "location": {"id": "ga4gh:SL.2_PBnFkjQSTGidfIkNH9Y95XH8t_8TZD", "type": "SequenceLocation", "digest": "2_PBnFkjQSTGidfIkNH9Y95XH8t_8TZD", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.C49OdjhPGBXjeiBVRZb2HYBbiYuYPtK_"}, "start": 383, "end": 384}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:337525", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:337525", "label": "erlotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C4436", "label": "Cholangiocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C4436", "label": "Cholangiocarcinoma", "mondo_id": "0019087"}}], "mappings": [{"coding": {"label": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "CHOL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:ERRFI1", "label": "ERRFI1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:18185"}], "type": "Gene"}}}
{"id": "moa.assertion:287", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:106", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:287", "label": "EZH2 p.Y646* (Nonsense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "148508726", "end_position": "148508726", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1938C>A", "protein_change": "p.Y646*", "exon": "16"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "287"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.XKHskuwaF4N1kY26E5A1RWt12H4dl_c9", "type": "Allele", "digest": "XKHskuwaF4N1kY26E5A1RWt12H4dl_c9", "location": {"id": "ga4gh:SL.7PJtwRMwSyrWxfU3VBIOb5LbGlGxJs2n", "type": "SequenceLocation", "digest": "7PJtwRMwSyrWxfU3VBIOb5LbGlGxJs2n", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 645, "end": 646}, "state": {"type": "LiteralSequenceExpression", "sequence": "*"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2274378", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2274378", "label": "tazemetostat"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3209", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3209", "label": "Follicular Lymphoma", "mondo_id": "0018906"}}], "mappings": [{"coding": {"label": "Follicular Lymphoma", "system": "https://oncotree.mskcc.org/", "code": "FL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EZH2", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "type": "Gene"}}}
{"id": "moa.assertion:288", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:106", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:288", "label": "EZH2 p.Y646F (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "148508727", "end_position": "148508727", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1937A>T", "protein_change": "p.Y646F", "exon": "16"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "288"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.oYK6HfZD2veVeRV_OCMXdMY8mM2k8riu", "type": "Allele", "digest": "oYK6HfZD2veVeRV_OCMXdMY8mM2k8riu", "location": {"id": "ga4gh:SL.7PJtwRMwSyrWxfU3VBIOb5LbGlGxJs2n", "type": "SequenceLocation", "digest": "7PJtwRMwSyrWxfU3VBIOb5LbGlGxJs2n", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 645, "end": 646}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2274378", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2274378", "label": "tazemetostat"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3209", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3209", "label": "Follicular Lymphoma", "mondo_id": "0018906"}}], "mappings": [{"coding": {"label": "Follicular Lymphoma", "system": "https://oncotree.mskcc.org/", "code": "FL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EZH2", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "type": "Gene"}}}
{"id": "moa.assertion:289", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:106", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:289", "label": "EZH2 p.Y646N (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "148508728", "end_position": "148508728", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1936T>A", "protein_change": "p.Y646N", "exon": "16"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "289"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.F3wf8X4pXaRvx55F_jvVkK258q-JoDni", "type": "Allele", "digest": "F3wf8X4pXaRvx55F_jvVkK258q-JoDni", "location": {"id": "ga4gh:SL.7PJtwRMwSyrWxfU3VBIOb5LbGlGxJs2n", "type": "SequenceLocation", "digest": "7PJtwRMwSyrWxfU3VBIOb5LbGlGxJs2n", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 645, "end": 646}, "state": {"type": "LiteralSequenceExpression", "sequence": "N"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2274378", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2274378", "label": "tazemetostat"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3209", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3209", "label": "Follicular Lymphoma", "mondo_id": "0018906"}}], "mappings": [{"coding": {"label": "Follicular Lymphoma", "system": "https://oncotree.mskcc.org/", "code": "FL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EZH2", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "type": "Gene"}}}
{"id": "moa.assertion:290", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:106", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:290", "label": "EZH2 p.A682G (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "148506467", "end_position": "148506467", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.2045C>G", "protein_change": "p.A682G", "exon": "18"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "290"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.0XRkkEA2HWTplj8pneW7IzKzkJh_VTdi", "type": "Allele", "digest": "0XRkkEA2HWTplj8pneW7IzKzkJh_VTdi", "location": {"id": "ga4gh:SL.K46cEnNhN_EnyHbnGqPUSZJsrdHH-Ema", "type": "SequenceLocation", "digest": "K46cEnNhN_EnyHbnGqPUSZJsrdHH-Ema", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 681, "end": 682}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2274378", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2274378", "label": "tazemetostat"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3209", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3209", "label": "Follicular Lymphoma", "mondo_id": "0018906"}}], "mappings": [{"coding": {"label": "Follicular Lymphoma", "system": "https://oncotree.mskcc.org/", "code": "FL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EZH2", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "type": "Gene"}}}
{"id": "moa.assertion:291", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:106", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:291", "label": "EZH2 p.A692V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "148506437", "end_position": "148506437", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2075C>T", "protein_change": "p.A692V", "exon": "18"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "291"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Asy9WpmrMOSunO4H7D3OU7t4MvIbBWK9", "type": "Allele", "digest": "Asy9WpmrMOSunO4H7D3OU7t4MvIbBWK9", "location": {"id": "ga4gh:SL.zgMYyYar7JOGCMcyd4F4CKRQMoBqM7qY", "type": "SequenceLocation", "digest": "zgMYyYar7JOGCMcyd4F4CKRQMoBqM7qY", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fZuyp1_QKM5vGWsn-O-CrPHPm5jR403J"}, "start": 691, "end": 692}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2274378", "label": "Tazemetostat", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2274378", "label": "tazemetostat"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3209", "label": "Follicular Lymphoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3209", "label": "Follicular Lymphoma", "mondo_id": "0018906"}}], "mappings": [{"coding": {"label": "Follicular Lymphoma", "system": "https://oncotree.mskcc.org/", "code": "FL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:EZH2", "label": "EZH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3527"}], "type": "Gene"}}}
{"id": "moa.assertion:294", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:26", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:294", "label": "FGFR3 p.R248C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "1803564", "end_position": "1803564", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.742C>T", "protein_change": "p.R248C", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "294"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913482"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.6fDQOuVnlKrDjTq3rkMY-1UHbT41h332", "type": "Allele", "digest": "6fDQOuVnlKrDjTq3rkMY-1UHbT41h332", "location": {"id": "ga4gh:SL.60nnfAgrzhZopUQU1HdoEDIqpIzQBOiE", "type": "SequenceLocation", "digest": "60nnfAgrzhZopUQU1HdoEDIqpIzQBOiE", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3"}, "start": 247, "end": 248}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2123125", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2123125", "label": "erdafitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C39851", "label": "Bladder Urothelial Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C39851", "label": "Bladder Urothelial Carcinoma", "mondo_id": "0005611"}}], "mappings": [{"coding": {"label": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BLCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:FGFR3", "label": "FGFR3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3690"}], "type": "Gene"}}}
{"id": "moa.assertion:295", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:26", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:295", "label": "FGFR3 p.S249C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "1803568", "end_position": "1803568", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.746C>G", "protein_change": "p.S249C", "exon": "6"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "295"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913483"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lCQZ8ie3k9M8N7wpd4BxHSpFYLKd0fVI", "type": "Allele", "digest": "lCQZ8ie3k9M8N7wpd4BxHSpFYLKd0fVI", "location": {"id": "ga4gh:SL.grxGJfSaMBBsfK5DECZSAECGGUC1gixU", "type": "SequenceLocation", "digest": "grxGJfSaMBBsfK5DECZSAECGGUC1gixU", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3"}, "start": 248, "end": 249}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2123125", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2123125", "label": "erdafitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C39851", "label": "Bladder Urothelial Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C39851", "label": "Bladder Urothelial Carcinoma", "mondo_id": "0005611"}}], "mappings": [{"coding": {"label": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BLCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:FGFR3", "label": "FGFR3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3690"}], "type": "Gene"}}}
{"id": "moa.assertion:296", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:26", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:296", "label": "FGFR3 p.G370C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "1806089", "end_position": "1806089", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1180G>T", "protein_change": "p.G370C", "exon": "8"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "296"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913479"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.jN7GBCtzW-TeO8Oj6sXOTBkb5RpqsnhE", "type": "Allele", "digest": "jN7GBCtzW-TeO8Oj6sXOTBkb5RpqsnhE", "location": {"id": "ga4gh:SL.BWL7lNkUDNtm3WnoyGpB-q0-58XpHTxt", "type": "SequenceLocation", "digest": "BWL7lNkUDNtm3WnoyGpB-q0-58XpHTxt", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3"}, "start": 369, "end": 370}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2123125", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2123125", "label": "erdafitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C39851", "label": "Bladder Urothelial Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C39851", "label": "Bladder Urothelial Carcinoma", "mondo_id": "0005611"}}], "mappings": [{"coding": {"label": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BLCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:FGFR3", "label": "FGFR3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3690"}], "type": "Gene"}}}
{"id": "moa.assertion:297", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:26", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:297", "label": "FGFR3 p.Y373C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "1806099", "end_position": "1806099", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.1118A>G", "protein_change": "p.Y373C", "exon": "8"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "297"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913485"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.UHA6S3oE8Ts_WI51w5noSpXhSlvNEjHu", "type": "Allele", "digest": "UHA6S3oE8Ts_WI51w5noSpXhSlvNEjHu", "location": {"id": "ga4gh:SL.g33H1Cf5jJONJO2upu64mfFipyfSK6MZ", "type": "SequenceLocation", "digest": "g33H1Cf5jJONJO2upu64mfFipyfSK6MZ", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xO86teDIIalLkqprCQaXyuvdPqvBxBG3"}, "start": 372, "end": 373}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2123125", "label": "Erdafitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2123125", "label": "erdafitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:569", "type": "Disease", "label": "Bladder cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9334"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C39851", "label": "Bladder Urothelial Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C39851", "label": "Bladder Urothelial Carcinoma", "mondo_id": "0005611"}}], "mappings": [{"coding": {"label": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BLCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:FGFR3", "label": "FGFR3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3690"}], "type": "Gene"}}}
{"id": "moa.assertion:304", "description": "A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:110", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.", "url": "https://doi.org/10.1038/leu.2013.14", "doi": "10.1038/leu.2013.14", "pmid": 23392356}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:304", "label": "FLT3 p.F691L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "13", "start_position": "28601361", "end_position": "28601361", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.2071T>C", "protein_change": "p.F691L", "exon": "17"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "304"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs759272576"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.fV8iAY2E_DdmWWtXswj2lJ4EP-DOasSU", "type": "Allele", "digest": "fV8iAY2E_DdmWWtXswj2lJ4EP-DOasSU", "location": {"id": "ga4gh:SL.yIDWm48UV7GUROvgzDYlMG6_5zH3C0E9", "type": "SequenceLocation", "digest": "yIDWm48UV7GUROvgzDYlMG6_5zH3C0E9", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 690, "end": 691}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C68936", "label": "Quizartinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C68936", "label": "Quizartinib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:FLT3", "label": "FLT3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "type": "Gene"}}}
{"id": "moa.assertion:305", "description": "Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:111", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.", "url": "https://doi.org/10.1038/sj.leu.2404374", "doi": "10.1038/sj.leu.2404374", "pmid": 16990784}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:305", "label": "FLT3 p.K663Q (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "13", "start_position": "28602381", "end_position": "28602381", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1987A>C", "protein_change": "p.K663Q", "exon": "16"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "305"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057520026"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.WGJhl7dROPj4jGUTJ3OS3-N5WX9F7rRR", "type": "Allele", "digest": "WGJhl7dROPj4jGUTJ3OS3-N5WX9F7rRR", "location": {"id": "ga4gh:SL.h_eLkMAzSINURuZpdCYvijoi9D-Eq4SG", "type": "SequenceLocation", "digest": "h_eLkMAzSINURuZpdCYvijoi9D-Eq4SG", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.0dtDG7QKyvW7BntvQVpLS83mYRA58LKH"}, "start": 662, "end": 663}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:357977", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:357977", "label": "sunitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:FLT3", "label": "FLT3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:3765"}], "type": "Gene"}}}
{"id": "moa.assertion:306", "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:112", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.", "url": "https://doi.org/10.1038/nature11143", "doi": "10.1038/nature11143", "pmid": 22722193}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:306", "label": "GATA3 p.M294K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "10", "start_position": "8106058", "end_position": "8106058", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.881T>A", "protein_change": "p.M294K", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "306"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.GmoEzlSokba5nA-T6hqd5PEHPrW1SGRI", "type": "Allele", "digest": "GmoEzlSokba5nA-T6hqd5PEHPrW1SGRI", "location": {"id": "ga4gh:SL.Ri61yshugFdINBQRYyWX74FvAPrs5k6o", "type": "SequenceLocation", "digest": "Ri61yshugFdINBQRYyWX74FvAPrs5k6o", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.bdosHg0m0-PjJbEXRptxUwqJcIlmb-z0"}, "start": 293, "end": 294}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:72965", "label": "Letrozole", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:72965", "label": "letrozole"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:572", "type": "Disease", "label": "Breast cancer", "mappings": [{"coding": {"system": "ncit", "code": "C9335"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:GATA3", "label": "GATA3", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:4172"}], "type": "Gene"}}}
{"id": "moa.assertion:310", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:115", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:310", "label": "IDH1 p.R132H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.395G>A", "protein_change": "p.R132H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "310"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:311", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with newly-diagnosed AML who are greater than or equal to 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy as well as relapsed or refractory AML.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:115", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:311", "label": "IDH1 p.R132C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.394C>T", "protein_change": "p.R132C", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "311"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "type": "Allele", "digest": "lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:312", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:115", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:310", "label": "IDH1 p.R132H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.395G>A", "protein_change": "p.R132H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "310"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C4436", "label": "Cholangiocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C4436", "label": "Cholangiocarcinoma", "mondo_id": "0019087"}}], "mappings": [{"coding": {"label": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "CHOL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:313", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA approved test with locally advanced or metastatic cholangiocarcinoma who have been previously treated.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:115", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf. Revised August 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:311", "label": "IDH1 p.R132C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.394C>T", "protein_change": "p.R132C", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "311"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "type": "Allele", "digest": "lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C4436", "label": "Cholangiocarcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C4436", "label": "Cholangiocarcinoma", "mondo_id": "0019087"}}], "mappings": [{"coding": {"label": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org/", "code": "CHOL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:316", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:116", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01915498"}, "relation": "exactMatch"}], "type": "Document", "title": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:316", "label": "IDH2 p.R140Q (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "90631934", "end_position": "90631934", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.419G>A", "protein_change": "p.R140Q", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "316"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913502"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.HK1caYli9110rSKDTqSXAgzjzajRFBBv", "type": "Allele", "digest": "HK1caYli9110rSKDTqSXAgzjzajRFBBv", "location": {"id": "ga4gh:SL.Oh1pTL0eECaO9-0FUtmM8h_iJqWu_zVO", "type": "SequenceLocation", "digest": "Oh1pTL0eECaO9-0FUtmM8h_iJqWu_zVO", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xop1Mrzn5Llu7Dj-BULoAd8Xmlbs-l-y"}, "start": 139, "end": 140}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1940332", "label": "Enasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1940332", "label": "enasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH2", "label": "IDH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5383"}], "type": "Gene"}}}
{"id": "moa.assertion:317", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:116", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01915498"}, "relation": "exactMatch"}], "type": "Document", "title": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:317", "label": "IDH2 p.R172S (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "90631837", "end_position": "90631837", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.516G>T", "protein_change": "p.R172S", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "317"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.GcEWQeOqTVsh88PUGeuMNT2jNcjCzshC", "type": "Allele", "digest": "GcEWQeOqTVsh88PUGeuMNT2jNcjCzshC", "location": {"id": "ga4gh:SL.UuG3IrLVJV7S2Qjtt99SWVQuiYDLlHxa", "type": "SequenceLocation", "digest": "UuG3IrLVJV7S2Qjtt99SWVQuiYDLlHxa", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xop1Mrzn5Llu7Dj-BULoAd8Xmlbs-l-y"}, "start": 171, "end": 172}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1940332", "label": "Enasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1940332", "label": "enasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH2", "label": "IDH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5383"}], "type": "Gene"}}}
{"id": "moa.assertion:318", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:116", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "mappings": [{"coding": {"system": "https://clinicaltrials.gov/search?term=", "code": "NCT01915498"}, "relation": "exactMatch"}], "type": "Document", "title": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:318", "label": "IDH2 p.R172K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "90631837", "end_position": "90631837", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.515G>A", "protein_change": "p.R172K", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "318"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.YqiDFzE2K6fcXhXkCGYHIQ75RgutPq_7", "type": "Allele", "digest": "YqiDFzE2K6fcXhXkCGYHIQ75RgutPq_7", "location": {"id": "ga4gh:SL.UuG3IrLVJV7S2Qjtt99SWVQuiYDLlHxa", "type": "SequenceLocation", "digest": "UuG3IrLVJV7S2Qjtt99SWVQuiYDLlHxa", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.xop1Mrzn5Llu7Dj-BULoAd8Xmlbs-l-y"}, "start": 171, "end": 172}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1940332", "label": "Enasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1940332", "label": "enasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH2", "label": "IDH2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5383"}], "type": "Gene"}}}
{"id": "moa.assertion:325", "description": "MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:118", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.", "url": "https://doi.org/10.1182/blood-2015-03-635821", "doi": "10.1182/blood-2015-03-635821", "pmid": 26443624}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:325", "label": "JAK1 p.V656F (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "65312353", "end_position": "65312353", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.1966G>T", "protein_change": "p.V656F", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "325"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.SR-Evc_MyfZ8NclBLvfIGIUzMokxIeml", "type": "Allele", "digest": "SR-Evc_MyfZ8NclBLvfIGIUzMokxIeml", "location": {"id": "ga4gh:SL.G3iyDI4-o7KiE_CkQGj-0jKIPQTZ0kxL", "type": "SequenceLocation", "digest": "G3iyDI4-o7KiE_CkQGj-0jKIPQTZ0kxL", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cu-mo9BHF4qdXH41R2iO9Zjkgjg9NZ94"}, "start": 655, "end": 656}, "state": {"type": "LiteralSequenceExpression", "sequence": "F"}}}, "therapeutic": {"id": "moa.normalize.therapy.drugbank:DB12638", "label": "PU-H71", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "drugbank:DB12638", "label": "PU-H71"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3167", "label": "Acute Lymphoid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3167", "label": "Acute Lymphoblastic Leukemia", "mondo_id": "0004967"}}], "mappings": [{"coding": {"label": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "ALL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:JAK1", "label": "JAK1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6190"}], "type": "Gene"}}}
{"id": "moa.assertion:326", "description": "MOHITO JAK1 A634D transplated mice were highly sensitive to growth inhibition by PU-H71.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:118", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.", "url": "https://doi.org/10.1182/blood-2015-03-635821", "doi": "10.1182/blood-2015-03-635821", "pmid": 26443624}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:326", "label": "JAK1 p.A634D (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "65312418", "end_position": "65312418", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1901C>A", "protein_change": "p.A634D", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "326"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs869312953"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.wh8gAcHF3JV7Gpq_p0v01r_dzRanXE7Z", "type": "Allele", "digest": "wh8gAcHF3JV7Gpq_p0v01r_dzRanXE7Z", "location": {"id": "ga4gh:SL.ESlAstIdoTQ3hoTqWtHY9I-PJz_OrjDg", "type": "SequenceLocation", "digest": "ESlAstIdoTQ3hoTqWtHY9I-PJz_OrjDg", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cu-mo9BHF4qdXH41R2iO9Zjkgjg9NZ94"}, "start": 633, "end": 634}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "moa.normalize.therapy.drugbank:DB12638", "label": "PU-H71", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "drugbank:DB12638", "label": "PU-H71"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3167", "label": "Acute Lymphoid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3167", "label": "Acute Lymphoblastic Leukemia", "mondo_id": "0004967"}}], "mappings": [{"coding": {"label": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "ALL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:JAK1", "label": "JAK1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6190"}], "type": "Gene"}}}
{"id": "moa.assertion:339", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:121", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:339", "label": "KIT p.T670I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55595519", "end_position": "55595519", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2009C>T", "protein_change": "p.T670I", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "339"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.w6K7bKlqZC_cCZOk9W0IBVh4EZrcSv3o", "type": "Allele", "digest": "w6K7bKlqZC_cCZOk9W0IBVh4EZrcSv3o", "location": {"id": "ga4gh:SL.IRTozCrHKQSKLYZ7gE862dBD7yFvLoFf", "type": "SequenceLocation", "digest": "IRTozCrHKQSKLYZ7gE862dBD7yFvLoFf", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 669, "end": 670}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1312397", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1312397", "label": "regorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:340", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:121", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:340", "label": "KIT p.V654A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55594258", "end_position": "55594258", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1961T>C", "protein_change": "p.V654A", "exon": "13"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "340"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913523"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.6mOBrBWsfWLavxBwhR3tMyJEW9UNc6fk", "type": "Allele", "digest": "6mOBrBWsfWLavxBwhR3tMyJEW9UNc6fk", "location": {"id": "ga4gh:SL.7uxXLSmztIxLhjUA87mxO2uukUSI-daq", "type": "SequenceLocation", "digest": "7uxXLSmztIxLhjUA87mxO2uukUSI-daq", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 653, "end": 654}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1312397", "label": "Regorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1312397", "label": "regorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}, {"id": "mesh:D015179", "type": "Disease", "label": "Colorectal Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C2956"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:342", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:122", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:339", "label": "KIT p.T670I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55595519", "end_position": "55595519", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2009C>T", "protein_change": "p.T670I", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "339"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913516"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.w6K7bKlqZC_cCZOk9W0IBVh4EZrcSv3o", "type": "Allele", "digest": "w6K7bKlqZC_cCZOk9W0IBVh4EZrcSv3o", "location": {"id": "ga4gh:SL.IRTozCrHKQSKLYZ7gE862dBD7yFvLoFf", "type": "SequenceLocation", "digest": "IRTozCrHKQSKLYZ7gE862dBD7yFvLoFf", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 669, "end": 670}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:357977", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:357977", "label": "sunitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:343", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:122", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:340", "label": "KIT p.V654A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55594258", "end_position": "55594258", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1961T>C", "protein_change": "p.V654A", "exon": "13"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "340"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913523"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.6mOBrBWsfWLavxBwhR3tMyJEW9UNc6fk", "type": "Allele", "digest": "6mOBrBWsfWLavxBwhR3tMyJEW9UNc6fk", "location": {"id": "ga4gh:SL.7uxXLSmztIxLhjUA87mxO2uukUSI-daq", "type": "SequenceLocation", "digest": "7uxXLSmztIxLhjUA87mxO2uukUSI-daq", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 653, "end": 654}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:357977", "label": "Sunitinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:357977", "label": "sunitinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:647", "type": "Disease", "label": "Pancreatic NET", "mappings": [{"coding": {"system": "ncit", "code": "C27720"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:660", "type": "Disease", "label": "Renal cell carcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C9385"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:347", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:347", "label": "KIT p.W557C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55593605", "end_position": "55593605", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1671G>T", "protein_change": "p.W557C", "exon": "11"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "347"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.vCHkLX559PRJOxY5nYLNi-0hqOXsMeYp", "type": "Allele", "digest": "vCHkLX559PRJOxY5nYLNi-0hqOXsMeYp", "location": {"id": "ga4gh:SL.UOky1zHhOtD4EN-Yk7t3jLSzfECIZtGr", "type": "SequenceLocation", "digest": "UOky1zHhOtD4EN-Yk7t3jLSzfECIZtGr", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 556, "end": 557}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:348", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:348", "label": "KIT p.W557G (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55593603", "end_position": "55593603", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1669T>G", "protein_change": "p.W557G", "exon": "11"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "348"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.aPCOkvmQ8zzAvdoKCE-6mjuY_BBCp-U8", "type": "Allele", "digest": "aPCOkvmQ8zzAvdoKCE-6mjuY_BBCp-U8", "location": {"id": "ga4gh:SL.UOky1zHhOtD4EN-Yk7t3jLSzfECIZtGr", "type": "SequenceLocation", "digest": "UOky1zHhOtD4EN-Yk7t3jLSzfECIZtGr", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 556, "end": 557}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:349", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:349", "label": "KIT p.W557R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55593603", "end_position": "55593603", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1669T>C", "protein_change": "p.W557R", "exon": "11"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "349"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.OjmqirAj5nGJsnlhajIto0yqlHtTzzG5", "type": "Allele", "digest": "OjmqirAj5nGJsnlhajIto0yqlHtTzzG5", "location": {"id": "ga4gh:SL.UOky1zHhOtD4EN-Yk7t3jLSzfECIZtGr", "type": "SequenceLocation", "digest": "UOky1zHhOtD4EN-Yk7t3jLSzfECIZtGr", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 556, "end": 557}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:350", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:350", "label": "KIT p.V559A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55593610", "end_position": "55593610", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1676T>C", "protein_change": "p.V559A", "exon": "11"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "350"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913517"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.KaXTQ-4MiJHF5w1ug1Vaku64sh9Y6Bdh", "type": "Allele", "digest": "KaXTQ-4MiJHF5w1ug1Vaku64sh9Y6Bdh", "location": {"id": "ga4gh:SL.XrP1UdH6iyt96D8ML4WbBtat0fZVEfzY", "type": "SequenceLocation", "digest": "XrP1UdH6iyt96D8ML4WbBtat0fZVEfzY", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 558, "end": 559}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:351", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:351", "label": "KIT p.V559G (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55593610", "end_position": "55593610", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1676T>G", "protein_change": "p.V559G", "exon": "11"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "351"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913517"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.dl4OeK6gWyW0u4C-FxAxCT8O08WWM9WV", "type": "Allele", "digest": "dl4OeK6gWyW0u4C-FxAxCT8O08WWM9WV", "location": {"id": "ga4gh:SL.XrP1UdH6iyt96D8ML4WbBtat0fZVEfzY", "type": "SequenceLocation", "digest": "XrP1UdH6iyt96D8ML4WbBtat0fZVEfzY", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 558, "end": 559}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:352", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:352", "label": "KIT p.L576P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55593661", "end_position": "55593661", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1727T>C", "protein_change": "p.L576P", "exon": "11"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "352"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913513"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.e3X8c8KxGdRvkl8YWKRk1o-84nRdiE3u", "type": "Allele", "digest": "e3X8c8KxGdRvkl8YWKRk1o-84nRdiE3u", "location": {"id": "ga4gh:SL.DuUZLfkfmGAgzUlRBT4SwtwdqDI5Zyf5", "type": "SequenceLocation", "digest": "DuUZLfkfmGAgzUlRBT4SwtwdqDI5Zyf5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 575, "end": 576}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:353", "description": "Imatinib (Gleevec) is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for patients with melanoma and KIT exon 11 and 13 variants; p.W557, p.V559, p.L576P, and p.K642E appear to have high level of sensitivity to KIT inhibition.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:124", "extensions": [{"type": "Extension", "name": "source_type", "value": "Guideline"}], "type": "Document", "title": "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "professional guideline evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000003"}, "variant": {"id": "moa.variant:353", "label": "KIT p.K642E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55594221", "end_position": "55594221", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.1924A>G", "protein_change": "p.K642E", "exon": "13"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "353"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Dsrq3AJXo4UQCiCnQCcrb2t551o9Dhv8", "type": "Allele", "digest": "Dsrq3AJXo4UQCiCnQCcrb2t551o9Dhv8", "location": {"id": "ga4gh:SL.OEWLQ_FjiJVB_F0lLzeEph15324HUuf-", "type": "SequenceLocation", "digest": "OEWLQ_FjiJVB_F0lLzeEph15324HUuf-", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 641, "end": 642}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:282388", "label": "Imatinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:282388", "label": "imatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:669", "type": "Disease", "label": "Systemic mastocytosis", "mappings": [{"coding": {"system": "ncit", "code": "C9235"}, "relation": "relatedMatch"}]}, {"id": "hemonc:582", "type": "Disease", "label": "Chronic myelogenous leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3174"}, "relation": "relatedMatch"}]}, {"id": "hemonc:24309", "type": "Disease", "label": "Acute lymphoblastic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3167"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}, {"id": "hemonc:602", "type": "Disease", "label": "Gastrointestinal stromal tumor", "mappings": [{"coding": {"system": "ncit", "code": "C3868"}, "relation": "relatedMatch"}]}, {"id": "hemonc:33893", "type": "Disease", "label": "Chronic myelogenous leukemia pediatric"}, {"id": "hemonc:667", "type": "Disease", "label": "Soft tissue sarcoma", "mappings": [{"coding": {"system": "ncit", "code": "C9306"}, "relation": "relatedMatch"}]}, {"id": "hemonc:616", "type": "Disease", "label": "Hypereosinophilic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C27038"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:360", "description": "Avapritnib inhibited the autophosphorylation of KIT p.D816V in cellular assays relative to wild-type KIT.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:127", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:360", "label": "KIT p.D816V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55599321", "end_position": "55599321", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2447A>T", "protein_change": "p.D816V", "exon": "17"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "360"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.nhiDwIq1klrGm3wtWO4a4BiS0jdW79Wd", "type": "Allele", "digest": "nhiDwIq1klrGm3wtWO4a4BiS0jdW79Wd", "location": {"id": "ga4gh:SL.FDPpCHrDqH_pR10oxpHZ17tyGhZXVnsj", "type": "SequenceLocation", "digest": "FDPpCHrDqH_pR10oxpHZ17tyGhZXVnsj", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.TcMVFj5kDODDWpiy1d_1-3_gOf4BYaAB"}, "start": 815, "end": 816}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2272107", "label": "Avapritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2272107", "label": "avapritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KIT", "label": "KIT", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6342"}], "type": "Gene"}}}
{"id": "moa.assertion:372", "description": "The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:130", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Amgen Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf. Revised May 2021. Accessed June 1st, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:372", "label": "KRAS p.G12C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "12", "start_position": "25398285", "end_position": "25398285", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.34G>T", "protein_change": "p.G12C", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "372"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.udBCHwlrf8xNiRy_19bLi-h5LhnZLgCt", "type": "Allele", "digest": "udBCHwlrf8xNiRy_19bLi-h5LhnZLgCt", "location": {"id": "ga4gh:SL.ovJR3lKrIflg4zDUU3Q-XH715XkwgTJl", "type": "SequenceLocation", "digest": "ovJR3lKrIflg4zDUU3Q-XH715XkwgTJl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2550714", "label": "Sotorasib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2550714", "label": "sotorasib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KRAS", "label": "KRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "type": "Gene"}}}
{"id": "moa.assertion:386", "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:69", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": 19915144}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:386", "label": "MAP2K1 p.P124L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66729163", "end_position": "66729163", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.371C>T", "protein_change": "p.P124L", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "386"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.8wkCi_XxSPbnuf_zYV1_SCcZ_pXVziQd", "type": "Allele", "digest": "8wkCi_XxSPbnuf_zYV1_SCcZ_pXVziQd", "location": {"id": "ga4gh:SL.Nll8Z8RN1jUIH9IAInO_9WEZSHMpnFNU", "type": "SequenceLocation", "digest": "Nll8Z8RN1jUIH9IAInO_9WEZSHMpnFNU", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 123, "end": 124}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:387", "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:69", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": 19915144}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:387", "label": "MAP2K1 p.Q56P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "387"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "type": "Allele", "digest": "yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "location": {"id": "ga4gh:SL.7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "type": "SequenceLocation", "digest": "7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 55, "end": 56}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:388", "description": "Presence of this variant may suggest resistance to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:69", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": 19915144}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:386", "label": "MAP2K1 p.P124L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66729163", "end_position": "66729163", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.371C>T", "protein_change": "p.P124L", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "386"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.8wkCi_XxSPbnuf_zYV1_SCcZ_pXVziQd", "type": "Allele", "digest": "8wkCi_XxSPbnuf_zYV1_SCcZ_pXVziQd", "location": {"id": "ga4gh:SL.Nll8Z8RN1jUIH9IAInO_9WEZSHMpnFNU", "type": "SequenceLocation", "digest": "Nll8Z8RN1jUIH9IAInO_9WEZSHMpnFNU", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 123, "end": 124}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:389", "description": "Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:138", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.", "url": "https://doi.org/10.1158/0008-5472.CAN-08-0099", "doi": "10.1158/0008-5472.CAN-08-0099", "pmid": 18632602}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:387", "label": "MAP2K1 p.Q56P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "387"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "type": "Allele", "digest": "yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "location": {"id": "ga4gh:SL.7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "type": "SequenceLocation", "digest": "7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 55, "end": 56}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:390", "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:139", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Trunzer, Kerstin, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology 31.14 (2013): 1767-1774.", "url": "https://doi.org/10.1200/JCO.2012.44.7888", "doi": "10.1200/JCO.2012.44.7888", "pmid": 23569304}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:387", "label": "MAP2K1 p.Q56P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "387"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "type": "Allele", "digest": "yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "location": {"id": "ga4gh:SL.7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "type": "SequenceLocation", "digest": "7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 55, "end": 56}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:391", "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:139", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Trunzer, Kerstin, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology 31.14 (2013): 1767-1774.", "url": "https://doi.org/10.1200/JCO.2012.44.7888", "doi": "10.1200/JCO.2012.44.7888", "pmid": 23569304}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:387", "label": "MAP2K1 p.Q56P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "387"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "type": "Allele", "digest": "yHQVVwZjma693Ev6lQtew1axCWVwIi8K", "location": {"id": "ga4gh:SL.7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "type": "SequenceLocation", "digest": "7Cb5uFiRT1XrF_e_d7_LIY1k3HodsnHA", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 55, "end": 56}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:392", "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:140", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.", "url": "https://doi.org/10.1200/JCO.2010.33.2312", "doi": "10.1200/JCO.2010.33.2312", "pmid": 21383288}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:392", "label": "MAP2K1 p.C121S (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66729153", "end_position": "66729153", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.361T>A", "protein_change": "p.C121S", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "392"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.FkanRNmwHE0Hf6xRjR2MElkUvP5kPMDC", "type": "Allele", "digest": "FkanRNmwHE0Hf6xRjR2MElkUvP5kPMDC", "location": {"id": "ga4gh:SL.i6W0RsEHM4RaSw3mTWR7uhZrhukaMdak", "type": "SequenceLocation", "digest": "i6W0RsEHM4RaSw3mTWR7uhZrhukaMdak", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 120, "end": 121}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:393", "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:140", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.", "url": "https://doi.org/10.1200/JCO.2010.33.2312", "doi": "10.1200/JCO.2010.33.2312", "pmid": 21383288}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:392", "label": "MAP2K1 p.C121S (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "15", "start_position": "66729153", "end_position": "66729153", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.361T>A", "protein_change": "p.C121S", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "392"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.FkanRNmwHE0Hf6xRjR2MElkUvP5kPMDC", "type": "Allele", "digest": "FkanRNmwHE0Hf6xRjR2MElkUvP5kPMDC", "location": {"id": "ga4gh:SL.i6W0RsEHM4RaSw3mTWR7uhZrhukaMdak", "type": "SequenceLocation", "digest": "i6W0RsEHM4RaSw3mTWR7uhZrhukaMdak", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.StlJo3M4b8cS253ufe9nPpWqQHBDOSPs"}, "start": 120, "end": 121}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K1", "label": "MAP2K1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6840"}], "type": "Gene"}}}
{"id": "moa.assertion:394", "description": "MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:76", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Wagle, Nikhil, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": 24265154}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:394", "label": "MAP2K2 p.Q60P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "19", "start_position": "4117541", "end_position": "4117541", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.179A>C", "protein_change": "p.Q60P", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "394"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs1057519808"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.vQTatXhzC7rdpHhUo-55WJmxKtpruDPT", "type": "Allele", "digest": "vQTatXhzC7rdpHhUo-55WJmxKtpruDPT", "location": {"id": "ga4gh:SL.2cJCGywm2trjsr5d5BTWZrFWC6UvqmtG", "type": "SequenceLocation", "digest": "2cJCGywm2trjsr5d5BTWZrFWC6UvqmtG", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fGPHz_BuC2mUP2mDkoh1KRbyO7QgvCFi"}, "start": 59, "end": 60}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAP2K2", "label": "MAP2K2", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6842"}], "type": "Gene"}}}
{"id": "moa.assertion:395", "description": "In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:141", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.", "url": "https://doi.org/10.1001/jamaoncol.2015.34", "doi": "10.1001/jamaoncol.2015.34", "pmid": 26181029}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:395", "label": "MAPK1 p.E322K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "22", "start_position": "22127164", "end_position": "22127164", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.964G>A", "protein_change": "p.E322K", "exon": "7"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "395"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.4yqg18xtnJP7cTJI-Z2xS5HjnhxJJg84", "type": "Allele", "digest": "4yqg18xtnJP7cTJI-Z2xS5HjnhxJJg84", "location": {"id": "ga4gh:SL.OkB7yCa0BFb9po8pwz7oojkE31xNbhRg", "type": "SequenceLocation", "digest": "OkB7yCa0BFb9po8pwz7oojkE31xNbhRg", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.N-m1tI22kffhKfdRZK8wCOR3QfI-1lfr"}, "start": 321, "end": 322}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:337525", "label": "Erlotinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:337525", "label": "erlotinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:648", "type": "Disease", "label": "Pancreatic cancer", "mappings": [{"coding": {"system": "ncit", "code": "C43298"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C34447", "label": "Head and Neck Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C34447", "label": "Head and Neck Squamous Cell Carcinoma", "mondo_id": "0010150"}}], "mappings": [{"coding": {"label": "Head and Neck Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "HNSC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MAPK1", "label": "MAPK1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6871"}], "type": "Gene"}}}
{"id": "moa.assertion:397", "description": "Presence of this variant may suggest sensitivity to SU11274.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:143", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.", "url": "https://doi.org/10.1158/0008-5472.CAN-08-2881", "doi": "10.1158/0008-5472.CAN-08-2881", "pmid": 19318576}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:397", "label": "MET p.T1010I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "116411990", "end_position": "116411990", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.3029C>T", "protein_change": "p.T1010I", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "397"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs56391007"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.hrgriXDdl95CwTxbXpun9v_Ekh_ERDNK", "type": "Allele", "digest": "hrgriXDdl95CwTxbXpun9v_Ekh_ERDNK", "location": {"id": "ga4gh:SL.-WoC2UeBw3g0dgpfWMsursnTS0_PQ_72", "type": "SequenceLocation", "digest": "-WoC2UeBw3g0dgpfWMsursnTS0_PQ_72", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.QITcgkaDXSK1bJllcGyJVlXeD_SiQdfo"}, "start": 991, "end": 992}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.iuphar.ligand:5057", "label": "SU11274", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "iuphar.ligand:5057", "label": "SU11274"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C34447", "label": "Head and Neck Squamous Cell Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C34447", "label": "Head and Neck Squamous Cell Carcinoma", "mondo_id": "0010150"}}], "mappings": [{"coding": {"label": "Head and Neck Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "HNSC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:MET", "label": "MET", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7029"}], "type": "Gene"}}}
{"id": "moa.assertion:427", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:427", "label": "NRAS p.Q61R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.182A>G", "protein_change": "p.Q61R", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "427"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.CpnlaV2B8565obATF-UlE706sBYp0D6M", "type": "Allele", "digest": "CpnlaV2B8565obATF-UlE706sBYp0D6M", "location": {"id": "ga4gh:SL.h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "type": "SequenceLocation", "digest": "h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:428", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:414", "label": "NRAS p.G12C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258748", "end_position": "115258748", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.34G>T", "protein_change": "p.G12C", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "414"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913250"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.7nsZiek_H62HpWGKFv1GLciGWv3tKRN5", "type": "Allele", "digest": "7nsZiek_H62HpWGKFv1GLciGWv3tKRN5", "location": {"id": "ga4gh:SL.bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "type": "SequenceLocation", "digest": "bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:429", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:415", "label": "NRAS p.G12D (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258747", "end_position": "115258747", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.35G>A", "protein_change": "p.G12D", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "415"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Rq3N-YIvM8zB_XQ0jSfgPNbpZpaXRjtd", "type": "Allele", "digest": "Rq3N-YIvM8zB_XQ0jSfgPNbpZpaXRjtd", "location": {"id": "ga4gh:SL.bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "type": "SequenceLocation", "digest": "bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:430", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:416", "label": "NRAS p.G12R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258748", "end_position": "115258748", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "p.34G>C", "protein_change": "p.G12R", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "416"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.8YIGJgiyUBzEbUeLEsiZkMcpSbUDb4-e", "type": "Allele", "digest": "8YIGJgiyUBzEbUeLEsiZkMcpSbUDb4-e", "location": {"id": "ga4gh:SL.bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "type": "SequenceLocation", "digest": "bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:431", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:417", "label": "NRAS p.G12S (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258748", "end_position": "115258748", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "p.34G>A", "protein_change": "p.G12S", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "417"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Pj1D4jmWU_aANZDjvMjoG4tEalP7Dyv6", "type": "Allele", "digest": "Pj1D4jmWU_aANZDjvMjoG4tEalP7Dyv6", "location": {"id": "ga4gh:SL.bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "type": "SequenceLocation", "digest": "bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:432", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:418", "label": "NRAS p.G12V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258747", "end_position": "115258747", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "p.35G>T", "protein_change": "p.G12V", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "418"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.WwV6JPwcMOAJu-ehDWQWmubmUWlV1ddk", "type": "Allele", "digest": "WwV6JPwcMOAJu-ehDWQWmubmUWlV1ddk", "location": {"id": "ga4gh:SL.bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "type": "SequenceLocation", "digest": "bjLwzqDNlAKLn0nHJdmYQoQpsq8Maob5", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:433", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:419", "label": "NRAS p.G13A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258744", "end_position": "115258744", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.38G>C", "protein_change": "p.G13A", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "419"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434596"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.aJRpUjcUzC-6TDCQpnDuV2umq1la3T1y", "type": "Allele", "digest": "aJRpUjcUzC-6TDCQpnDuV2umq1la3T1y", "location": {"id": "ga4gh:SL.NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "type": "SequenceLocation", "digest": "NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:434", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:420", "label": "NRAS p.G13D (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258744", "end_position": "115258744", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.38G>A", "protein_change": "p.G13D", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "420"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.QP0kq1DT5HXfhNPZg7qQUY8zLHQacZ3Y", "type": "Allele", "digest": "QP0kq1DT5HXfhNPZg7qQUY8zLHQacZ3Y", "location": {"id": "ga4gh:SL.NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "type": "SequenceLocation", "digest": "NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:435", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:421", "label": "NRAS p.G13R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258745", "end_position": "115258745", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.37G>C", "protein_change": "p.G13R", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "421"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.B7zZTxypiwSWZpc4LASs-CZL50acW3wA", "type": "Allele", "digest": "B7zZTxypiwSWZpc4LASs-CZL50acW3wA", "location": {"id": "ga4gh:SL.NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "type": "SequenceLocation", "digest": "NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:436", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:422", "label": "NRAS p.G13V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115258744", "end_position": "115258744", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.38G>T", "protein_change": "p.G13V", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "422"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121434596"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.xbKrlb4SMoteLcWJKz3pmPtxpiC4fHy-", "type": "Allele", "digest": "xbKrlb4SMoteLcWJKz3pmPtxpiC4fHy-", "location": {"id": "ga4gh:SL.NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "type": "SequenceLocation", "digest": "NHnKuGjGj3fgNXIz8vZqirV-Xpt31HaK", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 12, "end": 13}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:437", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:423", "label": "NRAS p.Q61E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115256530", "end_position": "115256530", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.181C>G", "protein_change": "p.Q61E", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "423"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913254"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.rsuK7OFWP7oiUdFoZerZmFu0nA6QBtSK", "type": "Allele", "digest": "rsuK7OFWP7oiUdFoZerZmFu0nA6QBtSK", "location": {"id": "ga4gh:SL.h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "type": "SequenceLocation", "digest": "h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:438", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:424", "label": "NRAS p.Q61H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115256528", "end_position": "115256528", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.183A>T", "protein_change": "p.Q61H", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "424"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913255"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.sUQrnY4jvb7whQHgnS6rkx08Lb44wowM", "type": "Allele", "digest": "sUQrnY4jvb7whQHgnS6rkx08Lb44wowM", "location": {"id": "ga4gh:SL.h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "type": "SequenceLocation", "digest": "h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:439", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:425", "label": "NRAS p.Q61L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.182A>T", "protein_change": "p.Q61L", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "425"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.qbbbxC4fGSEGvaT2Q9U8fLShG2YiTZL_", "type": "Allele", "digest": "qbbbxC4fGSEGvaT2Q9U8fLShG2YiTZL_", "location": {"id": "ga4gh:SL.h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "type": "SequenceLocation", "digest": "h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:440", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:426", "label": "NRAS p.Q61P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.182A>C", "protein_change": "p.Q61P", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "426"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs11554290"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.uUEOGctP2SXEXsexyo0cRbMNs9-g1kOf", "type": "Allele", "digest": "uUEOGctP2SXEXsexyo0cRbMNs9-g1kOf", "location": {"id": "ga4gh:SL.h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "type": "SequenceLocation", "digest": "h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:441", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:149", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": 18390968}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:427", "label": "NRAS p.Q61R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.182A>G", "protein_change": "p.Q61R", "exon": "3"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "427"}, "relation": "exactMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.CpnlaV2B8565obATF-UlE706sBYp0D6M", "type": "Allele", "digest": "CpnlaV2B8565obATF-UlE706sBYp0D6M", "location": {"id": "ga4gh:SL.h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "type": "SequenceLocation", "digest": "h9GUOAwTHOwzdimw1F8DSnIcZDhaLlLS", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18"}, "start": 60, "end": 61}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2289380", "label": "Selumetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2289380", "label": "selumetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3224", "label": "Melanoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3224", "label": "Melanoma", "mondo_id": "0005105"}}], "mappings": [{"coding": {"label": "Melanoma", "system": "https://oncotree.mskcc.org/", "code": "MEL"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:NRAS", "label": "NRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:7989"}], "type": "Gene"}}}
{"id": "moa.assertion:454", "description": "Avapritnib inhibited the autophosphorylation of PDGFRA p.D842V in cellular assays.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:127", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:453", "label": "PDGFRA p.D842V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55152093", "end_position": "55152093", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2525A>T", "protein_change": "p.D842V", "exon": "18"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "453"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Dy7soaZQU1vH9Eb93xG_pJyhu7xTDDC9", "type": "Allele", "digest": "Dy7soaZQU1vH9Eb93xG_pJyhu7xTDDC9", "location": {"id": "ga4gh:SL.xuh2OFm73UN7_0uLySrRY2Xe3FW7KJ5h", "type": "SequenceLocation", "digest": "xuh2OFm73UN7_0uLySrRY2Xe3FW7KJ5h", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2272107", "label": "Avapritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2272107", "label": "avapritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PDGFRA", "label": "PDGFRA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "type": "Gene"}}}
{"id": "moa.assertion:456", "description": "The U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a KIT inhibitor, for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor alpha (PDGFRA) exon 18 variant, including PDGFRA p.D842V.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:127", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:453", "label": "PDGFRA p.D842V (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "4", "start_position": "55152093", "end_position": "55152093", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2525A>T", "protein_change": "p.D842V", "exon": "18"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "453"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121908585"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Dy7soaZQU1vH9Eb93xG_pJyhu7xTDDC9", "type": "Allele", "digest": "Dy7soaZQU1vH9Eb93xG_pJyhu7xTDDC9", "location": {"id": "ga4gh:SL.xuh2OFm73UN7_0uLySrRY2Xe3FW7KJ5h", "type": "SequenceLocation", "digest": "xuh2OFm73UN7_0uLySrRY2Xe3FW7KJ5h", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.XpQn9sZLGv_GU3uiWO7YHq9-_alGjrVX"}, "start": 841, "end": 842}, "state": {"type": "LiteralSequenceExpression", "sequence": "V"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2272107", "label": "Avapritinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2272107", "label": "avapritinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": []}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3868", "label": "Gastrointestinal Stromal Tumor", "mondo_id": "0011719"}}], "mappings": [{"coding": {"label": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org/", "code": "GIST"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PDGFRA", "label": "PDGFRA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8803"}], "type": "Gene"}}}
{"id": "moa.assertion:461", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:461", "label": "PIK3CA p.E545Q (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936091", "end_position": "178936091", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.1633G>C", "protein_change": "p.E545Q", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "461"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.zDDKySmgMwFwLtAqrBXvNpQA_CQ5hToT", "type": "Allele", "digest": "zDDKySmgMwFwLtAqrBXvNpQA_CQ5hToT", "location": {"id": "ga4gh:SL.30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "type": "SequenceLocation", "digest": "30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:462", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:462", "label": "PIK3CA p.C420R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178927980", "end_position": "178927980", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1258T>C", "protein_change": "p.C420R", "exon": "8"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "462"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913272"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.FaMueqbbjnxuzxylH-4jpkaWfp6pLH98", "type": "Allele", "digest": "FaMueqbbjnxuzxylH-4jpkaWfp6pLH98", "location": {"id": "ga4gh:SL.xT667weGHtm7WR-yhHNnG5Jnp9cGQDW3", "type": "SequenceLocation", "digest": "xT667weGHtm7WR-yhHNnG5Jnp9cGQDW3", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 419, "end": 420}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:463", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:463", "label": "PIK3CA p.E542K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936082", "end_position": "178936082", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1624G>A", "protein_change": "p.E542K", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "463"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.ju5WwTji4SvLPzJqUB7EzSEF2DKtIusY", "type": "Allele", "digest": "ju5WwTji4SvLPzJqUB7EzSEF2DKtIusY", "location": {"id": "ga4gh:SL.8EJbFecCU_jsNjxLRhecipnh4mERYV3T", "type": "SequenceLocation", "digest": "8EJbFecCU_jsNjxLRhecipnh4mERYV3T", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:464", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:464", "label": "PIK3CA p.E542Q (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936082", "end_position": "178936082", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.1624G>C", "protein_change": "p.E542Q", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "464"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913273"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.WEA3Ixj_PrlgYlLocLDoaY2xgDeTqhF0", "type": "Allele", "digest": "WEA3Ixj_PrlgYlLocLDoaY2xgDeTqhF0", "location": {"id": "ga4gh:SL.8EJbFecCU_jsNjxLRhecipnh4mERYV3T", "type": "SequenceLocation", "digest": "8EJbFecCU_jsNjxLRhecipnh4mERYV3T", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 541, "end": 542}, "state": {"type": "LiteralSequenceExpression", "sequence": "Q"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:465", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:465", "label": "PIK3CA p.E545A (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936092", "end_position": "178936092", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.1634A>C", "protein_change": "p.E545A", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "465"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913274"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.dbKVUlhIwe3YS-B4Rhs5QsEI08yv0Xhk", "type": "Allele", "digest": "dbKVUlhIwe3YS-B4Rhs5QsEI08yv0Xhk", "location": {"id": "ga4gh:SL.30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "type": "SequenceLocation", "digest": "30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "A"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:466", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:466", "label": "PIK3CA p.E545D (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936093", "end_position": "178936093", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1635G>T", "protein_change": "p.E545D", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "466"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913275"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.E09IUKElemW2uoVRT5qacU7RMqT8Um5m", "type": "Allele", "digest": "E09IUKElemW2uoVRT5qacU7RMqT8Um5m", "location": {"id": "ga4gh:SL.30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "type": "SequenceLocation", "digest": "30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:467", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:466", "label": "PIK3CA p.E545D (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936093", "end_position": "178936093", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1635G>T", "protein_change": "p.E545D", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "466"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913275"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.E09IUKElemW2uoVRT5qacU7RMqT8Um5m", "type": "Allele", "digest": "E09IUKElemW2uoVRT5qacU7RMqT8Um5m", "location": {"id": "ga4gh:SL.30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "type": "SequenceLocation", "digest": "30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "D"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:468", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:468", "label": "PIK3CA p.E545G (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936092", "end_position": "178936092", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.1634A>G", "protein_change": "p.E545G", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "468"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913274"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.w50kYfxdOa7XBtTO7E3GrpFf0o-maldE", "type": "Allele", "digest": "w50kYfxdOa7XBtTO7E3GrpFf0o-maldE", "location": {"id": "ga4gh:SL.30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "type": "SequenceLocation", "digest": "30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:469", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:469", "label": "PIK3CA p.E545K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936091", "end_position": "178936091", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1633G>A", "protein_change": "p.E545K", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "469"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs104886003"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.-dMnJf9oUBfl9De0llc3LqJaGdFzfATK", "type": "Allele", "digest": "-dMnJf9oUBfl9De0llc3LqJaGdFzfATK", "location": {"id": "ga4gh:SL.30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "type": "SequenceLocation", "digest": "30Xk0lNcdOj15_Ymh9xUIrxa2wfFeLG7", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 544, "end": 545}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:470", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:470", "label": "PIK3CA p.G1049R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952090", "end_position": "178952090", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.3145G>C", "protein_change": "p.G1049R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "470"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913277"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.Llpd98XgE-ewhN4n29ycYLN8bW3fHAI_", "type": "Allele", "digest": "Llpd98XgE-ewhN4n29ycYLN8bW3fHAI_", "location": {"id": "ga4gh:SL.-NoH0THgMURtBj2JWZEqWf0MRuyMxOjz", "type": "SequenceLocation", "digest": "-NoH0THgMURtBj2JWZEqWf0MRuyMxOjz", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1048, "end": 1049}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:471", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:471", "label": "PIK3CA p.G1049S (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952090", "end_position": "178952090", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.3145G>A", "protein_change": "p.G1049S", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "471"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913277"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.GZ-HgAcZqv_Af6wmQPpEx9-cHdVHViC6", "type": "Allele", "digest": "GZ-HgAcZqv_Af6wmQPpEx9-cHdVHViC6", "location": {"id": "ga4gh:SL.-NoH0THgMURtBj2JWZEqWf0MRuyMxOjz", "type": "SequenceLocation", "digest": "-NoH0THgMURtBj2JWZEqWf0MRuyMxOjz", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1048, "end": 1049}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:472", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:472", "label": "PIK3CA p.H1047L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952085", "end_position": "178952085", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.3140A>T", "protein_change": "p.H1047L", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "472"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.3ybIkH_QhR6C7QmnTeD2-P6U1Pu7M__0", "type": "Allele", "digest": "3ybIkH_QhR6C7QmnTeD2-P6U1Pu7M__0", "location": {"id": "ga4gh:SL.g2PRcnni5_aM05W5Sh43vMyAu_JQqKwN", "type": "SequenceLocation", "digest": "g2PRcnni5_aM05W5Sh43vMyAu_JQqKwN", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:473", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:473", "label": "PIK3CA p.H1047R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952085", "end_position": "178952085", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.3140A>G", "protein_change": "p.H1047R", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "473"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913279"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.5GEqm-zIzvvPheyGb9rlu5DyIueIubXm", "type": "Allele", "digest": "5GEqm-zIzvvPheyGb9rlu5DyIueIubXm", "location": {"id": "ga4gh:SL.g2PRcnni5_aM05W5Sh43vMyAu_JQqKwN", "type": "SequenceLocation", "digest": "g2PRcnni5_aM05W5Sh43vMyAu_JQqKwN", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:474", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:474", "label": "PIK3CA p.H1047Y (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952084", "end_position": "178952084", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.3139C>T", "protein_change": "p.H1047Y", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "474"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913281"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.H9BsFCFdYyh8KDICE_3wSsjLy66SWFYS", "type": "Allele", "digest": "H9BsFCFdYyh8KDICE_3wSsjLy66SWFYS", "location": {"id": "ga4gh:SL.g2PRcnni5_aM05W5Sh43vMyAu_JQqKwN", "type": "SequenceLocation", "digest": "g2PRcnni5_aM05W5Sh43vMyAu_JQqKwN", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1046, "end": 1047}, "state": {"type": "LiteralSequenceExpression", "sequence": "Y"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:475", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:475", "label": "PIK3CA p.H701P (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178938860", "end_position": "178938860", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.2102A>C", "protein_change": "p.H701P", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "475"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913282"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.e9nTDXWkejhFpPUKdRxAn89wET-ZUv9N", "type": "Allele", "digest": "e9nTDXWkejhFpPUKdRxAn89wET-ZUv9N", "location": {"id": "ga4gh:SL.MWrmsRMn6TvIhvI7SpI7S2e-Zf0KhgnT", "type": "SequenceLocation", "digest": "MWrmsRMn6TvIhvI7SpI7S2e-Zf0KhgnT", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 700, "end": 701}, "state": {"type": "LiteralSequenceExpression", "sequence": "P"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:476", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:476", "label": "PIK3CA p.M1043I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952074", "end_position": "178952074", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.3129G>A", "protein_change": "p.M1043I", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "476"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913283"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.A8crPBRvgFrkcWWnszjqT26E08kr0wV0", "type": "Allele", "digest": "A8crPBRvgFrkcWWnszjqT26E08kr0wV0", "location": {"id": "ga4gh:SL.dBQ0L7KEO0plRNml9X1ArMWe2LfTPZEa", "type": "SequenceLocation", "digest": "dBQ0L7KEO0plRNml9X1ArMWe2LfTPZEa", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1042, "end": 1043}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:477", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:476", "label": "PIK3CA p.M1043I (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952074", "end_position": "178952074", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.3129G>A", "protein_change": "p.M1043I", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "476"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913283"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.A8crPBRvgFrkcWWnszjqT26E08kr0wV0", "type": "Allele", "digest": "A8crPBRvgFrkcWWnszjqT26E08kr0wV0", "location": {"id": "ga4gh:SL.dBQ0L7KEO0plRNml9X1ArMWe2LfTPZEa", "type": "SequenceLocation", "digest": "dBQ0L7KEO0plRNml9X1ArMWe2LfTPZEa", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1042, "end": 1043}, "state": {"type": "LiteralSequenceExpression", "sequence": "I"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:478", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:478", "label": "PIK3CA p.P539R (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936074", "end_position": "178936074", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.1616C>G", "protein_change": "p.P539R", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "478"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913285"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.zS_-FFo-cPjizcBEraRCMJ-wfCLNXM9F", "type": "Allele", "digest": "zS_-FFo-cPjizcBEraRCMJ-wfCLNXM9F", "location": {"id": "ga4gh:SL.kB-menfpSkfiqgHhlrz5qpp-EMn9QMOB", "type": "SequenceLocation", "digest": "kB-menfpSkfiqgHhlrz5qpp-EMn9QMOB", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 538, "end": 539}, "state": {"type": "LiteralSequenceExpression", "sequence": "R"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:479", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:479", "label": "PIK3CA p.Q546K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178936094", "end_position": "178936094", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.1636C>A", "protein_change": "p.Q546K", "exon": "10"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "479"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913286"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.jW54ta30v7-SnUy7YFCuq4niqSws7FSt", "type": "Allele", "digest": "jW54ta30v7-SnUy7YFCuq4niqSws7FSt", "location": {"id": "ga4gh:SL.kA49q6hKdCYHX4Ucwy1WP5ui46p4HO9-", "type": "SequenceLocation", "digest": "kA49q6hKdCYHX4Ucwy1WP5ui46p4HO9-", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 545, "end": 546}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:480", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:58", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": 20453058}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "preclinical evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000009"}, "variant": {"id": "moa.variant:480", "label": "PIK3CA p.Y1021C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "3", "start_position": "178952007", "end_position": "178952007", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.3062A>G", "protein_change": "p.Y1021C", "exon": "21"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "480"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913288"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.8aRynLgwo0OYPIuCyiw6BGNd8oLxoGXx", "type": "Allele", "digest": "8aRynLgwo0OYPIuCyiw6BGNd8oLxoGXx", "location": {"id": "ga4gh:SL.RqqpcDDSnYjohL2f5iG7fvIP05N2h3D-", "type": "SequenceLocation", "digest": "RqqpcDDSnYjohL2f5iG7fvIP05N2h3D-", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.km8C9FORJbErpAh7Ub63pZLUzEm-au9D"}, "start": 1020, "end": 1021}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C165479", "label": "Pictilisib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C165479", "label": "Pictilisib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C9245", "label": "Invasive Breast Carcinoma", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C9245", "label": "Invasive Breast Carcinoma", "mondo_id": "0006256"}}], "mappings": [{"coding": {"label": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org/", "code": "BRCA"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:PIK3CA", "label": "PIK3CA", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:8975"}], "type": "Gene"}}}
{"id": "moa.assertion:521", "description": "Certain missesnse mutations may predict resistance to RET inhibitors", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:159", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.", "url": "https://doi.org/10.1093/annonc/mdy137", "doi": "10.1093/annonc/mdy137", "pmid": 29912274}], "predicate": "predictsResistanceTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:521", "label": "RET p.V804M (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "10", "start_position": "43614996", "end_position": "43614996", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2410G>A", "protein_change": "p.V804M", "exon": "14"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "521"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs79658334"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.1oFFaTlmKzBPBb4fiyAGEilaWJ4sce8_", "type": "Allele", "digest": "1oFFaTlmKzBPBb4fiyAGEilaWJ4sce8_", "location": {"id": "ga4gh:SL.JTFULP7527QHOIvMFCmBW5vura0q1KjT", "type": "SequenceLocation", "digest": "JTFULP7527QHOIvMFCmBW5vura0q1KjT", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 803, "end": 804}, "state": {"type": "LiteralSequenceExpression", "sequence": "M"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2370147", "label": "LOXO-292", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2370147", "label": "selpercatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3879", "label": "Medullary Thyroid Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3879", "label": "Thyroid Gland Medullary Carcinoma", "mondo_id": "0015277"}}], "mappings": [{"coding": {"label": "Medullary Thyroid Cancer", "system": "https://oncotree.mskcc.org/", "code": "THME"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:RET", "label": "RET", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "type": "Gene"}}}
{"id": "moa.assertion:522", "description": "Certain missesnse mutations may predict sensitivity to RET inhibitors", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:159", "extensions": [{"type": "Extension", "name": "source_type", "value": "Journal"}], "type": "Document", "title": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.", "url": "https://doi.org/10.1093/annonc/mdy137", "doi": "10.1093/annonc/mdy137", "pmid": 29912274}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "observational study evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000007"}, "variant": {"id": "moa.variant:522", "label": "RET p.M918T (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "10", "start_position": "43617416", "end_position": "43617416", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.2753T>C", "protein_change": "p.M918T", "exon": "16"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "522"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs74799832"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.hEybNB_CeKflfFhT5AKOU5i1lgZPP-aS", "type": "Allele", "digest": "hEybNB_CeKflfFhT5AKOU5i1lgZPP-aS", "location": {"id": "ga4gh:SL.oIeqSfOEuqO7KNOPt8YUIa9vo1f6yMao", "type": "SequenceLocation", "digest": "oIeqSfOEuqO7KNOPt8YUIa9vo1f6yMao", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.jMu9-ItXSycQsm4hyABeW_UfSNRXRVnl"}, "start": 917, "end": 918}, "state": {"type": "LiteralSequenceExpression", "sequence": "T"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2370147", "label": "LOXO-292", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2370147", "label": "selpercatinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}, {"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3879", "label": "Medullary Thyroid Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3879", "label": "Thyroid Gland Medullary Carcinoma", "mondo_id": "0015277"}}], "mappings": [{"coding": {"label": "Medullary Thyroid Cancer", "system": "https://oncotree.mskcc.org/", "code": "THME"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:RET", "label": "RET", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:9967"}], "type": "Gene"}}}
{"id": "moa.assertion:814", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:235", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:310", "label": "IDH1 p.R132H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.395G>A", "protein_change": "p.R132H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "310"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:815", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:235", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:311", "label": "IDH1 p.R132C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.394C>T", "protein_change": "p.R132C", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "311"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "type": "Allele", "digest": "lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:816", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:235", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:310", "label": "IDH1 p.R132H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.395G>A", "protein_change": "p.R132H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "310"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.ctid:q8-EQ3sEvpFi9GFxwRkBI4-kW-qt4Ka0", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1251", "label": "Azacitidine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1251", "label": "azacitidine"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:583", "type": "Disease", "label": "Chronic myelomonocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3178"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:817", "description": "The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:235", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Servier Pharmaceuticals LLC. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf. Revised May 2022. Accessed July 7th, 2022.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:311", "label": "IDH1 p.R132C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.394C>T", "protein_change": "p.R132C", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "311"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "type": "Allele", "digest": "lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.ctid:q8-EQ3sEvpFi9GFxwRkBI4-kW-qt4Ka0", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1251", "label": "Azacitidine", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1251", "label": "azacitidine"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}, {"id": "hemonc:583", "type": "Disease", "label": "Chronic myelomonocytic leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3178"}, "relation": "relatedMatch"}]}, {"id": "hemonc:634", "type": "Disease", "label": "Myelodysplastic syndrome", "mappings": [{"coding": {"system": "ncit", "code": "C3247"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:859", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:254", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:311", "label": "IDH1 p.R132C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.394C>T", "protein_change": "p.R132C", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "311"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "type": "Allele", "digest": "lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C129687", "label": "Olutasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C129687", "label": "Olutasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:860", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:254", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:310", "label": "IDH1 p.R132H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.395G>A", "protein_change": "p.R132H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "310"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C129687", "label": "Olutasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C129687", "label": "Olutasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:861", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:254", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:861", "label": "IDH1 p.R132G (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.394C>G", "protein_change": "p.R132G", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "861"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.aAXNeFGBgeJUGbun-bKvgoW204tC1xdp", "type": "Allele", "digest": "aAXNeFGBgeJUGbun-bKvgoW204tC1xdp", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "G"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C129687", "label": "Olutasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C129687", "label": "Olutasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:862", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:254", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:862", "label": "IDH1 p.R132S (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.394C>A", "protein_change": "p.R132S", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "862"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.y-ioX4e_ySwP_LlplLNp0cz04a8BBr9H", "type": "Allele", "digest": "y-ioX4e_ySwP_LlplLNp0cz04a8BBr9H", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "S"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C129687", "label": "Olutasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C129687", "label": "Olutasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:863", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to Rezlidhia (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:254", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed January 5, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:863", "label": "IDH1 p.R132L (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.395G>T", "protein_change": "p.R132L", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "863"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2zh_S3hn7AWJd00rhirLhhDW8VcVBo9N", "type": "Allele", "digest": "2zh_S3hn7AWJd00rhirLhhDW8VcVBo9N", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "L"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C129687", "label": "Olutasidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C129687", "label": "Olutasidenib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3171", "label": "Acute Myeloid Leukemia", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3171", "label": "Acute Myeloid Leukemia", "mondo_id": "0018874"}}], "mappings": [{"coding": {"label": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org/", "code": "AML"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:864", "description": "The U.S. Food and Drug Administration (FDA) has granted approval to adagrasib for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:255", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised Dec 2022. Accessed January 5th, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:372", "label": "KRAS p.G12C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "12", "start_position": "25398285", "end_position": "25398285", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.34G>T", "protein_change": "p.G12C", "exon": "2"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "372"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913530"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.udBCHwlrf8xNiRy_19bLi-h5LhnZLgCt", "type": "Allele", "digest": "udBCHwlrf8xNiRy_19bLi-h5LhnZLgCt", "location": {"id": "ga4gh:SL.ovJR3lKrIflg4zDUU3Q-XH715XkwgTJl", "type": "SequenceLocation", "digest": "ovJR3lKrIflg4zDUU3Q-XH715XkwgTJl", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS"}, "start": 11, "end": 12}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.ncit:C157493", "label": "Adagrasib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "ncit:C157493", "label": "Adagrasib"}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:KRAS", "label": "KRAS", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:6407"}], "type": "Gene"}}}
{"id": "moa.assertion:867", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:258", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:mm4iftPYmDnZsAZWZwRW5l7p9lbvwqOJ", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:1424911", "label": "Dabrafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1424911", "label": "dabrafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:642", "type": "Disease", "label": "Non-small cell lung cancer", "mappings": [{"coding": {"system": "ncit", "code": "C2926"}, "relation": "relatedMatch"}]}, {"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:675", "type": "Disease", "label": "Thyroid cancer", "mappings": [{"coding": {"system": "ncit", "code": "C7510"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:1425098", "label": "Trametinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1425098", "label": "trametinib dimethyl sulfoxide"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.oncotree:LGGNOS", "label": "Low-Grade Glioma, NOS", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "oncotree:LGGNOS", "label": "Low-Grade Glioma, NOS", "mondo_id": null}}], "mappings": [{"coding": {"label": "Low-Grade Glioma, NOS", "system": "https://oncotree.mskcc.org/", "code": "LGGNOS"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:911", "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:268", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:310", "label": "IDH1 p.R132H (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113112", "end_position": "209113112", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.395G>A", "protein_change": "p.R132H", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "310"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913500"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "H"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3247", "label": "Myelodysplastic Syndromes", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3247", "label": "Myelodysplastic Syndrome", "mondo_id": "0018881"}}], "mappings": [{"coding": {"label": "Myelodysplastic Syndromes", "system": "https://oncotree.mskcc.org/", "code": "MDS"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:912", "description": "The U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible IDH1 mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:268", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:311", "label": "IDH1 p.R132C (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "2", "start_position": "209113113", "end_position": "209113113", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.394C>T", "protein_change": "p.R132C", "exon": "4"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "311"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913499"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "type": "Allele", "digest": "lAST62ntkEaXy6RDDOF1V4C3jd-jaAJ5", "location": {"id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ"}, "start": 131, "end": 132}, "state": {"type": "LiteralSequenceExpression", "sequence": "C"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:2049873", "label": "Ivosidenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049873", "label": "ivosidenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:580", "type": "Disease", "label": "Cholangiocarcinoma", "mappings": [{"coding": {"system": "ncit", "code": "C4436"}, "relation": "relatedMatch"}]}, {"id": "hemonc:552", "type": "Disease", "label": "Acute myeloid leukemia", "mappings": [{"coding": {"system": "ncit", "code": "C3171"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C3247", "label": "Myelodysplastic Syndromes", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C3247", "label": "Myelodysplastic Syndrome", "mondo_id": "0018881"}}], "mappings": [{"coding": {"label": "Myelodysplastic Syndromes", "system": "https://oncotree.mskcc.org/", "code": "MDS"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:IDH1", "label": "IDH1", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:5382"}], "type": "Gene"}}}
{"id": "moa.assertion:913", "description": "The U.S. Food and Drug Administration (FDA) approved encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:269", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.ctid:Ghu43xXqJAxMIyWjnLPSz84j2Mav-wAL", "extensions": [{"type": "Extension", "name": "moa_therapy_type", "value": "Targeted therapy"}], "type": "CombinationTherapy", "components": [{"id": "moa.normalize.therapy.rxcui:2049122", "label": "Binimetinib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049122", "label": "binimetinib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, {"id": "moa.normalize.therapy.rxcui:2049106", "label": "Encorafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:2049106", "label": "encorafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "ChEMBL", "has_indications": [{"id": "mesh:D008545", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "mesh:D009369", "type": "Disease", "label": "Neoplasms", "mappings": [{"coding": {"system": "ncit", "code": "C3262"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}]}, "tumorType": {"id": "moa.normalize.disease.ncit:C2926", "label": "Non-Small Cell Lung Cancer", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C2926", "label": "Lung Non-Small Cell Carcinoma", "mondo_id": "0005233"}}], "mappings": [{"coding": {"label": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org/", "code": "NSCLC"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:946", "description": "The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:273", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed January 30, 2024.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:144", "label": "BRAF p.V600E (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "144"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs113488022"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "E"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C53972", "label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C53972", "label": "Erdheim-Chester Disease", "mondo_id": "0018153"}}], "mappings": [{"coding": {"label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "system": "https://oncotree.mskcc.org/", "code": "ECD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}
{"id": "moa.assertion:947", "description": "The U.S. Food and Drug Administration (FDA) approved vemurafenib for the treatment of patients with Erdheim-Chester disease and whose tumors harbor a BRAF V600 mutation.", "type": "VariantTherapeuticResponseStudy", "specifiedBy": {"id": "moa.method:2021", "label": "MOAlmanac (2021)", "type": "Method", "isReportedIn": {"label": "Reardon, B., Moore, N.D., Moore, N.S. et al.", "type": "Document", "title": "Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology", "doi": "10.1038/s43018-021-00243-3", "pmid": 35121878}}, "isReportedIn": [{"id": "moa.source:273", "extensions": [{"type": "Extension", "name": "source_type", "value": "FDA"}], "type": "Document", "title": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed January 30, 2024.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf"}], "predicate": "predictsSensitivityTo", "direction": "none", "strength": {"label": "FDA recognized evidence", "system": "https://go.osu.edu/evidence-codes", "code": "e000002"}, "variant": {"id": "moa.variant:146", "label": "BRAF p.V600K (Missense)", "extensions": [{"type": "Extension", "name": "MOA representative coordinate", "value": {"chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "exon": "15"}}], "mappings": [{"coding": {"system": "https://moalmanac.org/api/features/", "code": "146"}, "relation": "exactMatch"}, {"coding": {"system": "https://www.ncbi.nlm.nih.gov/snp/", "code": "rs121913227"}, "relation": "relatedMatch"}], "type": "ProteinSequenceConsequence", "definingContext": {"id": "ga4gh:VA.pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "type": "Allele", "digest": "pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "location": {"id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": {"type": "SequenceReference", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y"}, "start": 599, "end": 600}, "state": {"type": "LiteralSequenceExpression", "sequence": "K"}}}, "therapeutic": {"id": "moa.normalize.therapy.rxcui:1147220", "label": "Vemurafenib", "extensions": [{"type": "Extension", "name": "therapy_normalizer_data", "value": {"normalized_id": "rxcui:1147220", "label": "vemurafenib"}}, {"type": "Extension", "name": "regulatory_approval", "value": {"approval_rating": "FDA", "has_indications": [{"id": "hemonc:629", "type": "Disease", "label": "Melanoma", "mappings": [{"coding": {"system": "ncit", "code": "C3224"}, "relation": "relatedMatch"}]}, {"id": "hemonc:594", "type": "Disease", "label": "Erdheim-Chester disease", "mappings": [{"coding": {"system": "ncit", "code": "C53972"}, "relation": "relatedMatch"}]}]}}], "type": "TherapeuticAgent"}, "tumorType": {"id": "moa.normalize.disease.ncit:C53972", "label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "extensions": [{"type": "Extension", "name": "disease_normalizer_data", "value": {"normalized_id": "ncit:C53972", "label": "Erdheim-Chester Disease", "mondo_id": "0018153"}}], "mappings": [{"coding": {"label": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "system": "https://oncotree.mskcc.org/", "code": "ECD"}, "relation": "exactMatch"}], "type": "Disease"}, "qualifiers": {"alleleOrigin": "somatic", "geneContext": {"id": "moa.normalize.gene:BRAF", "label": "BRAF", "extensions": [{"type": "Extension", "name": "gene_normalizer_id", "value": "hgnc:1097"}], "type": "Gene"}}}